



December 2020 Thursday 3 - Monday 7

17th Global Cardiovascular Clinical Trialists Forum

Clinical Trial Science At Its Best

www.globalcvctforum.com



17th Global CardioVascular Clinical Trialists Forum

Table of contents _____

FACULTY LIST	03
PROGRAM-AT-A-GLANCE	06/07
• Thursday, December 3rd	10
• Friday, December 4th	17
• Saturday, December 5th	06
• Sunday, December 6th	30
• Monday, December 7th	36
YOUNG INVESTIGATORS	41
SPEAKER BIOGRAPHIES	49

www.globalcvctforum.com

Faculty list

Academy

01. William Abraham (Columbus, USA)
02. Kirkwood Adams (Chapel Hill, USA)
03. Amanda Adler (Oxford, GBR)
04. Rajiv Agarwal (Indianapolis, USA)
05. Inder Anand (San Diego, USA)
06. Dominick Angiolillo (Jacksonville, USA)
07. Stefan Anker (Berlin, GER)
08. Charalambos Antoniades (Oxford, GBR)
09. Paul W. Armstrong (Alberta, CAN)
10. Suzanne Arnold (Kansas City, USA)
11. Michel Azizi (Paris, FRA)
12. George Bakris (Chicago, USA)
13. Sripal Bangalore (New York, USA)
14. Nir Barzilai (New York, USA)
15. Jeffrey Borer (New York, USA)
16. Barry Borlaug (Minneapolis, USA)
17. Deepak Bhatt (Boston, USA)
18. Biykem Bozkurt (Houston, USA)
19. Eugene Braunwald (Boston, USA)
20. Javed Butler (Jackson, USA)
21. Robert Califf (Verily, USA)
22. Davide Cao (New York, USA)
23. Davide Capodanno (Catania, ITA)
24. Peter Carson (Chapel Hill, USA)
25. Barbara Casadei (London, GBR)
26. Michael Charlton (Chicago, USA)
27. John Cleland (Glasgow, GBR)
28. Jan H. Cornel (Nijmegen, NED)
29. Donald Cutlip (Boston, USA)
30. Thibaud Damy (Paris, FRA)
31. George Dargatzis (New York, USA)
32. Christopher deFilippi (Washington, USA)
33. David DeMets (Madison, USA)
34. Thomas Deering (Atlanta, USA)
35. Susan Ellenberg (Philadelphia, USA)
36. Murray Epstein (Miami, USA)
37. Michael Felker (Durham, USA)
38. Joao Ferreira (Nancy, FRA)
39. Gemma Figtree (Sydney, AUS)
40. Gerasimos Filippatos (Athens, GRE)
41. Bernard Gersh (Rochester, USA)
42. Michael Gibson (Boston, USA)
43. Robert Giugliano (Boston, USA)
44. Chris Granger (Durham, USA)
45. John Gregson (London, GBR)
46. Barry Greenberg (La Jolla, USA)
47. Mayra Guerrero (Rochester, USA)
48. Rebecca Hahn (New York, USA)
49. Stephen Harrison (San Antonio, USA)
50. Hiddo Heerspink (Groningen, NED)
51. Timothy Henry (Los Angeles, USA)
52. Howard Herrmann (Philadelphia, USA)
53. Adrian Hernandez (Durham, USA)
54. Ziad Hijazi (Uppsala, SWE)
55. Joseph A. Hill (Dallas, USA)
56. Gerhard Hindricks (Leipzig, GER)
57. Carolyn Ho (Boston, USA)
58. Elaine Hylek (Boston, USA)
59. Tiny Jaarsma (Linköping, SWE)
60. Dan Jacoby (New Haven, USA)
61. Stefan James (Uppsala, SWE)
62. Ewa Jankowska (Wrocław, POL)
63. Meg Jardine (Sydney, AUS)
64. Hasan Jilani (New York, USA)
65. David Kao (Denver, USA)
66. Navin Kapur (Boston, USA)
67. Padma Kaul (Edmonton, CAN)
68. Wolfgang Koenig (Munich, GER)
69. Mikhail Kosiborod (Missouri, USA)
70. Stephen Kritchevsky (Winston-Salem, USA)
71. Harlan Krumholz (New Haven, USA)
72. Dharam Kumbhani (Dallas, USA)
73. Ulf Landmesser (Berlin, GER)
74. Carolyn Lam (Singapore, SIN)
75. Peter Libby (Boston, USA)
76. Cecilia Linde (Stockholm, SWE)
77. JoAnn Lindenfeld (Nashville, USA)
78. Teresa Lopez Fernandez (Madrid, ESP)
79. Michael Mack (Plano, USA)
80. Andrea Maier (Melbourne, AUS)
81. Shami Mahmud (La Jolla, USA)
82. Douglas Mann (Saint Louis, USA)
83. Daniel Mark (Durham, USA)
84. Marty Maron (Boston, USA)
85. Alexandre Mebazaa (Paris, FRA)
86. Mandeep Mehra (Boston, USA)
87. Roxana Mehran (New York, USA)
88. Robert Mentz (Durham, USA)
89. Erin Michos (Baltimore, USA)
90. Sankar Navaneethan (Houston, USA)
91. Steven Nissen (Cleveland, USA)
92. Patrick O'Gara (Boston, USA)
93. Iacopo Olivetto (Florence, ITA)
94. Rebecca Ortega (Durham, USA)
95. Milton Packer (Dallas, USA)
96. Marc Pfeffer (Boston, USA)
97. Jonathan Piccini (Durham, USA)
98. Burkert Pieske (Berlin, GER)
99. Ileana Piña (Detroit, USA)
100. Bertram Pitt (Ann Arbor, USA)
101. Stuart Pocock (London, GBR)
102. Piotr Ponikowski (Wrocław, POL)
103. David Preiss (Oxford, GBR)
104. Sunil Rao (Durham, USA)
105. Kausik Ray (London, GBR)
106. Vivek Reddy (New York, USA)
107. Paul Ridker (Boston, USA)
108. Julio Rosenstock (Dallas, USA)
109. Peter Rossing (Copenhagen, DEN)
110. Patrick Rossignol (Nancy, FRA)
111. Andrea Russo (Camden, USA)
112. Donna Ryan (Baton Rouge, USA)
113. Sandra Sanders-van Wijk (Maastricht, NED)

Faculty list

- 114. Arun Sanyal (Richmond, USA)
- 115. Naveed Sattar (Glasgow, GBR)
- 116. Michael Schmoeckel (Asklepios, GER)
- 117. Benjamin Scirica (Boston, USA)
- 118. Michele Senni (Bergamo, ITA)
- 119. Sanjiv Shah (Chicago, USA)
- 120. Abhinav Sharma (Montreal, CAN)
- 121. Tabassome Simon (Paris, FRA)
- 122. Scott Solomon (Boston, USA)
- 123. John Spertus (Kansas City, USA)
- 124. Lynne Stevenson (Nashville, USA)
- 125. Jean-Claude Tardif (Montreal, CAN)
- 126. John Teerlink (San Francisco, USA)
- 127. Jeffrey Testani (New Haven, USA)
- 128. Holger Thiele (Leipzig, GER)
- 129. Jan Tijssen (Naarden, NED)
- 130. Vinod Thourani (Atlanta, USA)
- 131. Mintu Turakhia (Stanford, USA)
- 132. Katherine Tuttle (Seattle, USA)
- 133. Muthiah Vaduganathan (Boston, USA)
- 134. Harriette Van Spall (Hamilton, CAN)
- 135. Subodh Verma (Toronto, CAN)
- 136. Annabelle Volgman (Chicago, USA)
- 137. Lars Wallentin (Stockholm, SWE)
- 138. Christoph Wanner (Würzburg, GER)
- 139. Mary Walsh (Baltimore, USA)
- 140. David Wheeler (London, GBR)
- 141. Stephan Windecker (Bern, CHE)
- 142. Lijing Yan (Kunshan, CHN)
- 143. Faiez Zannad (Nancy, FRA)

Journal

- 144. Joseph Alpert (American J Medicine, Tucson, USA)
- 145. Filippo Crea (Eur Heart Journal, ITA)
- 146. Robert Golub (JAMA, Washington, USA)
- 147. John Jarcho (NEJM, Boston, USA)
- 148. Stuart Spencer (The Lancet, London, GBR)

Media

- 149. Martha Gulati (Phoenix, USA)
- 150. Larry Husten (CVCTCardioBrief, USA)

Social media ambassadors

- 151. Alex Newbar (CVCTCardiobrief, USA)
- 152. Lucrecia Maria Burgos (Buenos Aires, ARG)
- 153. Rajiv Sankaranarayanan (Liverpool, GBR)
- 154. Rachna Kataria (New York, USA)
- 155. Vanessa Blumer (Durham, USA)
- 156. Ersilia M. DeFilippis (Boston, USA)
- 157. Diego Araiza Garaygordobil (Mexico City, MEX)
- 158. Paola Morejón Barragán (Buenos Aires, ARG)
- 159. Kevin Shah (Salt Lake City, USA)
- 160. M Chadi Alraies (Detroit, USA)
- 161. Ekaterini Lambrinou (Limassol, Cyprus)

Industry

- 162. Brooke Allocco (Boston Scientific, USA)
- 163. Thomas Andersson (AstraZeneca, SWE)
- 164. Jodi Akin (Hawthorne Effect, USA)
- 165. Luke Bamber (Bayer, GER)
- 166. Elliot Barnathan (JnJ, USA)
- 167. Adriane Berg (Kinexum, USA)
- 168. Agim Beshiri (Abbott Dx, USA)
- 169. François Henri Boissel (Novadiscovery, FRA)
- 170. Antonieta Bomfim Wirtz (Bayer, GER)
- 171. Karine Bourgeois (4TEEN4 Pharmaceuticals GmbH, GER)
- 172. Martina Brueckmann (Boehringer Ingelheim, GER)
- 173. Daniel Burkhoff (Cardiovascular Research Foundation, USA)
- 174. Manu Chakravarthy (Axcella, USA)
- 175. Cathy Chen (Daiichi Sankyo, USA)

- 176. Erin Rees Clayton (Good Food Institute, USA)
- 177. Thomas Clozel (Owkin, France)
- 178. Graziella Collu (AstraZeneca, SWE)
- 179. Gad Cotter (Momentum Research, USA)
- 180. Beth Davison (Momentum Research, USA)
- 181. Michael Davidson (Corvidia Therapeutics, USA)
- 182. Efthymios Deliaris (Cytosorbents, USA)
- 183. Howard Dittich (Cirius Pharmaceutical, USA)
- 184. Saliu Drilon (Philips, USA)
- 185. Jay Edelberg (BMS, USA)
- 186. Irina Elyubaeva (Servier, FRA)
- 187. Alexander Fleming (Kinexum, USA)
- 188. Steven Gough (NovoNordisk, DEN)
- 189. Craig Granowitz (Amarin, USA)
- 190. Abraham Gutman (AG Mednet, USA)
- 191. Sibylle Hauske (Boehringer Ingelheim, GER)
- 192. Narimon Honarpour (Amgen, USA)
- 193. Jianying Hu (IBM, USA)
- 194. Thomas Idorn (NovoNordisk, USA)
- 195. Waheed Jamal (Boehringer Ingelheim, GER)
- 196. Klaus Jensen (Vifor Pharma, CHE)
- 197. Jennifer Jones (Abbott Vascular, USA)
- 198. Amer Joseph (Bayer, GER)
- 199. Hovingh Kees (NovoNordisk, DEN)
- 200. Mehmood Khan (Life Biosciences, USA)
- 201. Bronwyn Kingwell (CSL, AUS)
- 202. Robert Kowal (Medtronic, USA)
- 203. Tamara Krcmar (Servier, FRA)
- 204. Maria Kubin (Bayer, GER)
- 205. Christopher Kurtz (Amgen, USA)
- 206. Anissa Lamarque (Olink, FRA)
- 207. Anna-Maria Langkilde (AstraZeneca, SWE)
- 208. Jack Lawrence (Janssen, USA)
- 209. Martin Lefkowitz (Novartis, USA)
- 210. Fady Malik (Cytokinetics, USA)
- 211. Laura Mauri (Medtronic, USA)
- 212. Pieter Muntendam (G3Pharmaceuticals, USA)

Faculty list

- 213. Manuela Negoita (Medtronic, USA)
- 214. Richard Nkulikiyinka (Bayer, GER)
- 215. Matias Nordaby (Boehringer Ingelheim, GER)
- 216. Mahesh Patel (MSD, USA)
- 217. Riccardo Perfetti (Applied Therapeutics, USA)
- 218. Jeffrey Popma (Medtronic, USA)
- 219. James Revkin (Pfizer, USA)
- 220. Jeffrey Riesmeyer (Lilly, USA)
- 221. Lothar Roessig (Bayer, GER)
- 222. Jerome Rossert (AstraZeneca, SWE)
- 223. Dan Schaber (Medtronic, USA)
- 224. William Smith (Alexion, USA)
- 225. Monica Shah (IQVIA, USA)
- 226. Salim Shah (Sarfez, USA)
- 227. Chuck Simonton, (Abiomed, USA)
- 228. Bergur Stefansson (AstraZeneca, SWE)
- 229. Kenneth Stein (Boston Scientific, USA)
- 230. James Strait (Merck, USA)
- 231. Kartik Sundareswaran (Abbott, USA)
- 232. Thomas Thum (Cardior Pharmaceuticals, GER)
- 233. Thomas Thuren (Novartis, USA)
- 234. Benoit Tyl (Servier, FRA)
- 235. Martin Unverdorben (Daiichi-Sankyo, USA)
- 236. Claire Varin (Servier, FRA)
- 237. Ola Vedin (Boehringer Ingelheim, GER)
- 238. Janet Wittes (Washington, USA)
- 239. Hans Juergen Woerle (Nestlé HealthScience, CHE)
- 240. Fred Yang (KBP Biosciences, USA)
- 241. Nadim Yared (CVRx, USA)
- 242. Andre Ziegler (Roche Dx, CHE)

Regulatory

- 243. Fernando Aguel (FDA, USA)
- 244. Majd AlGhatrif (NIH, USA)

- 245. Angeles Alonso (MHRA, GBR)
- 246. Frank Anania (FDA, USA)
- 247. Ariel Ash-Shakoor (FDA, USA)
- 248. Jennifer Bastijanic (FDA, USA)
- 249. Nikolai Brun (EMA, DEN)
- 250. Preston Dunnmon (FDA, USA)
- 251. Kan Fang (FDA, USA)
- 252. Andrew Farb (FDA, USA)
- 253. Luigi Ferrucci (NIH, USA)
- 254. Lawrence Fine (NHLBI, USA)
- 255. Charu Gandotra (FDA, USA)
- 256. Lydia Glaw (FDA, USA)
- 257. Nicole Ibrahim (FDA, USA)
- 258. Robert Kazmierski (FDA, USA)
- 259. Maciej Kostrubiec (EMA, POL)
- 260. Michael Lauer (NIH, USA)
- 261. Adrian Magee (FDA, USA)
- 262. Peter Mol (EMA, NED)
- 263. Mauro Moscucci (FDA, USA)
- 264. Elektra Papadopoulos (FDA, USA)
- 265. Bakul Patel (FDA, USA)
- 266. Jessica Paulsen (FDA, USA)
- 267. Gail Pearson (NHLBI, USA)
- 268. Krishna Prasad (MRHA, GBR)
- 269. Ivor Pritchard (office for Human Research Protections, USA)
- 270. Jaime Raben (FDA, USA)
- 271. Giuseppe Rosano (MRHA, GBR)
- 272. Yves Rosenberg (NHLBI, USA)
- 273. John Sapirstein (FDA, USA)
- 274. Fred Senatore (FDA, USA)
- 275. John Sharretts (FDA, USA)
- 276. Meir Shinnar (FDA, USA)
- 277. Norman Stockbridge (FDA, USA)
- 278. Aliza Thompson (FDA, USA)
- 279. Ellis Unger (FDA, USA)

- 280. George Van Hare (FDA, USA)
- 281. Bernard Vasseur (FDA, USA)
- 282. Changfu Wu (FDA, USA)
- 283. Lisa Yanoff (FDA, USA)
- 284. Emmanouil Zouridakis (MHRA, GBR)
- 285. Bram Zuckerman (FDA, USA)

Patients

- 286. Jacqueline Alikhaani (Los Angeles, USA)
- 287. Sadegh Alikhaani (Los Angeles, USA)
- 288. Marc Bains (Vancouver, CAN)
- 289. Cynthia Chauhan (Wichita, USA)
- 290. Patrick Gee (Chesterfield, USA)
- 291. Penilla Gunther (Stockholm, SWE)
- 292. Nick Hartshorne-Evans (Pumping Marvellous Foundation, GBR)
- 293. Denis Janssen (Zuid, NED)
- 294. Steve Macari (Poitiers, FRA)
- 295. Robin Martinez (Denver, USA)
- 296. Greg Merritt (Ann Arbor, USA)
- 297. Wanda F Moore (Tucson, USA)
- 298. Bray Patrick-Lake (Durham, USA)
- 299. Juddson Rupp (Charlotte, USA)
- 300. Lisa Salberg (HCMA, USA)
- 301. Jeff Sloan (Rochester, USA)
- 302. Marjorie Smelstor (Kansas City, USA)
- 303. Marietta Verbakel (Nijmegen, NED)
- 304. Jayna Williams (New Hampshire, USA)

Payer / Economist

- 305. Andrew Briggs (LSHTM, GBR)
- 306. Martin Cowie (Imperial College London, GBR)
- 309. Adrian Jonas (NICE, London, GBR)

Program at a glance

DAY 1 – THURSDAY, DECEMBER 3RD, 2020

THEATRE	13:30 14:00	14:00 14:30	14:30 15:00	15:00 15:30	15:30 16:00	16:00 16:30	16:30 17:00	17:00 17:30	17:30 18:00	18:00 18:30	18:30 19:00	19:00 19:30	19:30 20:00	20:00 20:30	20:30 21:00	21:00 21:30
	ELECTROPHYSIOLOGY 1				BREAK	ELECTROPHYSIOLOGY 2			DATA SCIENCE AND INFORMATION TECHNOLOGY			SGLT2i TRIALS IN CKD				
	HOW HFREF THERAPY LANDSCAPE WILL CHANGE			TRIAL CONDUCT POST COVID					ELECTROPHYSIOLOGY 2			BREAK	NASH AND OBESITY TRIALS2			
									iCVCT 1 INTERVENTIONAL CT DURING COVID			CV PRECISION MEDICINE				

DAY 2 – FRIDAY, DECEMBER 4TH, 2020

THEATRE	13:30 14:00	14:00 14:30	14:30 15:00	15:00 15:30	15:30 16:00	16:00 16:30	16:30 17:00	17:00 17:30	17:30 18:00	18:00 18:30	18:30 19:00	19:00 19:30	19:30 20:00	20:00 20:30	20:30 21:00	21:00 21:30
LIBERTÉ	THE VALUE OF BIOMARKERS IN TRIALS				BREAK	MRA TRIALS IN DIABETES KIDNEY DISEASE				BREAK	KEYNOTE	MRA TRIALS IN HYPERTENSION AND CKD				
EGALITÉ	EVIDENCE GAPS IN WOMENS CV HEALTH					HOW TO IMPROVE WOMENS LEADERSHIP BREAK					BREAK	LESSONS LEARNT FROM THE COVID CRISIS				
FRATERNITÉ	THE 2020 FDA DIABETES GUIDANCE					FOOD AND DIET HEALTH SCIENCE										

DAY 3 – SATURDAY, DECEMBER 5TH, 2020

THEATRE	13:30 14:00	14:00 14:30	14:30 15:00	15:00 15:30	15:30 16:00	16:00 16:30	16:30 17:00	17:00 17:30	17:30 18:00	18:00 18:30	18:30 19:00	19:00 19:30	19:30 20:00	20:00 20:30	20:30 21:00	21:00 21:30
	SGLT2 INHIBITORS HF TRIALS				BREAK	PATIENTS ENGAGEMENT				BREAK	PATIENT REPORTED OUTCOMES					
	ATHEROSCLEROSIS 1					ATHEROSCLEROSIS 2					ATHEROSCLEROSIS 3					
	iCVCT 2 TRIALS ON HIGH BLEEDING RISK PATIENTS				BREAK	CARDIOMYOPATHIES 1					CARDIOMYOPATHIES 2					

Program at a glance

DAY 4 – SUNDAY, DECEMBER 6TH, 2020

THEATRE	13:30 14:00	14:00 14:30	14:30 15:00	15:00 15:30	15:30 16:00	16:00 16:30	16:30 17:00	17:00 17:30	17:30 18:00	18:00 18:30	18:30 19:00	19:00 19:30	19:30 20:00	20:00 20:30
	iCVCT 3 MITRAL AND TRICUSPID VALVE TRIALS			BREAK	iCVCT 4 CORONARY INTERVENTION TRIALS			BREAK	iCVCT 5 DAPT CONSIDERATIONS IN PATIENTS POST PCI					
	THE EXPERIMENTAL PARADIGM DURING COVID				VERICIGUAT VICTORIA				CARDIO KIDNEY TRIALS					
	iCVCT 6 HF DEVICES				HEALTHY AGING				PAYERS VALUATION OF CLINICAL EVIDENCE					

DAY 5 – MONDAY, DECEMBER 7TH, 2020

THEATRE	13:30 14:00	14:00 14:30	14:30 15:00	15:00 15:30	15:30 16:00	16:00 16:30	16:30 17:00	17:00 17:30	17:30 18:00	18:00 18:30	18:30 19:00	19:00 19:30	19:30 20:00	20:00 20:30
	iCVCT 7 SHOCK AND STEMI TRIALS				BREAK	iCVCT 8 STEMI trials				BREAK	iCVCT 9 TAVR TRIALS			
	THE FUTURE OF HFREF TRIALS					IRON THERAPY					PATHWAYS TO ENHANCE BIOMARKER VALUE			

www.globalcvctforum.com

Topical Tracks

Clinical Trial Science – Design – Conduct – Interpretation

- Data Science And Information Technology Revolutionizing Clinical Trials
- The Transformation Of Trial Conduct Post Covid. How To Keep The Best?
- Making CV Precision Medicine Become a Reality
- European Heart Journal - CVCT-WOMEN AS ONE Joint Session Session - Evidence Gaps In Women's Cardiovascular Health
- CVCT-WOMEN AS ONE Joint Session - How To Improve Women's Leadership As Clinical Trialists?
- Operational Shifts In Trial Conduct - Learnt From The Covid-19 Crisis
- Patient Engagement Is More Than A Catchphrase: One Patient Does Not Engagement Make
- "Nullius In Verba": The Crisis Of The Experimental Paradigm During The Covid-19 Pandemic
- How Payers Are Prepared To Value. Clinical Evidence In Cardiovascular Medicine?

Biomarkers Trials – Biomarkers in Trials

- The Value Of Biomarkers In Trials
- Pathways To Enhance Biomarker Value – Imaging Innovation

HEART FAILURE – ARRHYTHMIA TRIALS

- Old Therapies, New Twists And Science Gaps In Electrophysiology: What Do We Do Next?
- Digital Health To Jumpstart A New Era In Electrophysiology
- Understanding And Interpreting The Results Of SglT2i Trials In Ckd
- How The HFrEF Therapy Landscape Will Change?
- The Future Of MRA Trials In Hypertension And Cardiorenal Disease
- Understanding The Results Of SGLT2 Inhibitors Heart Failure Trials
- Patient Reported Outcomes Validity And Valuation
- Mechanistically Targeted Therapy In Cardiomyopathies
- Path To Approval And Implementation Of Cardiomyopathies Drug
- Targeting The Vessels And The Heart. Oral Soluble Guanylate Cyclase Stimulator (Vericiguat) And Cardiac Myosin Activator (Omecamtiv Mecarbil)
- The Future Of HFReF Trials
- Iron Therapy In Heart Failure. From Trial Evidence To Implementation

www.globalcvctforum.com

Topical Tracks

Interventional Cardiology Trials

- iCVCT 1: Interventional Clinical Trials In The Time Of Covid - Challenges For Device Studies In Interventional Therapies
- iCVCT 2: Trials And Tribulations On High Bleeding Risk Patients
- iCVCT 3: Mitral And Tricuspid Valve Devices Trials
- iCVCT 4: Coronary Intervention Trials. Complex Patients- Complex Lesions Trials
- iCVCT 5: Dapt Considerations In Patients Post PCI Trials
- iCVCT 6: Breakthrough Heart Failure Devices
- iCVCT 7: Shock And Stemi Trials - Hemodynamic Support In Shock
- iCVCT 8: Stemi Trials
- iCVCT 9: Tavr Trials. Remaining Questions, Challenges, Controversies In Approval Pathways

Cardiometabolic – Atherosclerosis – Diet – Ageing Trials

- NASH AND OBESITY TRIALS - Part 1: CHANGING PARADIGM
- NASH AND OBESITY TRIALS - Part 2: MULTI STAKEHOLDERS' FORUM
- How Will The Removal Of Requirement For CVOT From The 2020 FDA Diabetes Guidance Shape The Future Of Trial Design?
- Evidence Generation In Food And Diet Health Science
- Atherosclerosis Trials Part 1: Traditional Targets And Innovative Approaches
- Atherosclerosis Trials Part 2: How Clinical Trials Help Progressing The Inflammation Hypothesis In Cvd?
- Atherosclerosis Trials Part 3: Approval, Implementation And Reimbursement Challenges
- Increasing Healthspan. The Next Frontier For Clinical Trialists

Cardiokidney Trials

- Understanding And Interpreting The Results Of Mineralocorticoid Receptor Antagonists Trials In Diabetes Kidney Disease
- CKD And Cardio-Kidney Trials. Seeing The Forest For The Trees

Day 1 - Thursday, December 3, 2020

OLD THERAPIES, NEW TWISTS AND SCIENCE GAPS IN ELECTROPHYSIOLOGY: WHAT DO WE DO NEXT?

Moderators: Gerhard Hindricks (Leipzig, GER) & Elaine Hylek (Boston, USA)

Thursday, December 3rd

13:30 – 15:30 Central European Time (CET)



Atrial Fibrillation Trials

• Rhythm Control and Updating Guidelines Post EAST

Gerhard Hindricks (Leipzig, GER)

• Left Atrial Appendage Closure VS DOAC Therapy: Hard Outcomes, Quality of Life And Cost-Effectiveness Valuation

Vivek Reddy (New York, USA)

• Device-Detected AF: Treat Or Wait For More Science?

Cecilia Linde (Stockholm, SWE)

Innovation In Cardiac Implantable Electronic Devices: Do We Need Randomized Trials To Compare Safety And Efficacy?

• Leadless Pacing VS Standard Transvenous Pacing. Weighing the Evidence

Jonathan Piccini (Durham, USA)

• Totally Subcutaneous SCD VS Transvenous ICD Beyond PRAETORIAN And UNTOUCHED. The Basis For Patient-Shared Decision-Making?

Thomas Deering (Atlanta, USA)

Assessing The Totality Of Evidence For Optimal Implementation Of Electrophysiology Therapies

Andrea Russo (Camden, USA)

THE LIVE FORUM

Multi-Stakeholder Moderated Debate

HOW TO PROGRESS FROM NEW EVIDENCE TO IMPLEMENTATION?

Moderators: Gerhard Hindricks (Leipzig, GER) & Elaine Hylek (Boston, USA)

Panelists: Thomas Deering (Atlanta, USA), Kan Fang (FDA, USA), Robert Kowal (Medtronic, USA), Cecilia Linde (Stockholm, SWE), Jonathan Piccini (Durham, USA), Vivek Reddy (New York, USA), Giuseppe Rosano (MHRA, GBR), Andrea Russo (Camden, USA), Kenneth Stein (Boston Scientific, USA), George Van Hare (FDA, USA)

DIGITAL HEALTH TO JUMPSTART A NEW ERA IN ELECTROPHYSIOLOGY

Moderators: Cecilia Linde (Stockholm, SWE) & Andrea Russo (Camden, USA)

Thursday, December 3rd

16:00 – 17:30 Central European Time (CET)



New Approaches & Technology To Streamline EP Trial Execution And Trial Results Adoption

Jonathan Piccini (Durham, USA)

Industry Viewpoint

Robert Kowal (Medtronic, USA), Kenneth Stein (Boston Scientific, USA)

Patient viewpoint

Jeff Sloan (Rochester, USA)

Regulatory Viewpoint

George Van Hare (FDA, USA), Giuseppe Rosano (MHRA, GBR)

Day 1 - Thursday, December 3, 2020

THE LIVE FORUM

Multi-Stakeholder Moderated Debate

DIGITAL HEALTH TO JUMPSTART A NEW ERA IN ELECTROPHYSIOLOGY

Moderators: Cecilia Linde (Stockholm, SWE) & Andrea Russo (Camden, USA)

Panelists: Thomas Deering (Atlanta, USA), Gerhard Hindricks (Leipzig, GER), Elaine Hylek (Boston, USA), Robert Kowal (Medtronic, USA), Jessica Paulsen (FDA, USA), Jonathan Piccini (Durham, USA), Vivek Reddy (New York, USA), Giuseppe Rosano (MHRA, GBR), Jeff Sloan (Rochester, USA), Kenneth Stein (Boston Scientific, USA), George Van Hare (FDA, USA)

DATA SCIENCE AND INFORMATION TECHNOLOGY REVOLUTIONIZING CLINICAL TRIALS.

Moderators: Adrian Hernandez (Durham, USA), Harlan Krumholz (New Haven, USA)

Thursday, December 3rd

17:30 – 19:30 Central European Time (CET)



Benefits And Challenges Using Electronic Medical Records For Clinical Research

David Kao (Denver, USA)

Artificial Intelligence For Patient Screening In Clinical Trials

Jianying Hu (IBM, USA)

Simulated Outcome Modelling For Enhanced Future Trial Design

François Henri Boissel (Novartis, FRA), Thomas Clozel (Owkin, France)

Data Science For Automated Endpoint Adjudication?

Abraham Gutman (AG Mednet, USA)

Office For Human Research Protections Viewpoint

Ivor Pritchard (Office for Human Research Protections, USA)

Regulatory Viewpoint

Nikolai Brun (EMA, DEN), Bakul Patel (FDA, USA)

The LIVE Forum

Multi-Stakeholder Moderated Debate

DIGITAL HEALTH TO JUMPSTART A NEW ERA IN ELECTROPHYSIOLOGY

Moderators: Adrian Hernandez (Durham, USA) & Harlan Krumholz (New Haven, USA)

Panelists: François Henri Boissel (Novartis, FRA), Nikolai Brun (EMA, DEN), Thomas Clozel (Owkin, France), Abraham Gutman (AG Mednet, USA), Jianying Hu (IBM, USA), David Kao (Denver, USA), Bakul Patel (FDA, USA), Ivor Pritchard (Office for Human Research Protections, USA), Harriette Van Spall (Hamilton, CAN)

www.globalcvctforum.com

Day 1 - Thursday, December 3, 2020

UNDERSTANDING AND INTERPRETING THE RESULTS OF SGLT2i TRIALS IN CKD

Moderators: Patrick Rossignol (Nancy, FRA) & Katherine Tuttle (Seattle, USA)

Thursday, December 3rd

19:30 – 21:30 Central European Time (CET)



DAPA CKD main results and new findings

Hiddo Heerspink (Groningen, NED), David Wheeler (London, GBR)

Target Population, To What Patients SGLT2i Apply?

Peter Rossing (Copenhagen, DEN)

External Validity And Meta-Analysis Of CKD Outcomes Trials

Meg Jardine (Sydney, AUS)

What Is Next? EMPA-Kidney

Christoph Wanner (Würzburg, GER)

Mechanistic Plausibility

Jeffrey Testani (New Haven, USA)

The Potential For GLP-1ras In Improving Cardio-Renal Outcomes. Rationale And Concept Of The FLOW Trial

Katherine Tuttle (Seattle, USA)

The LIVE Forum

Multi-Stakeholder Moderated Debate

UNDERSTANDING AND INTERPRETING THE RESULTS OF SGLT2i TRIALS IN CKD

Moderators: Patrick Rossignol (Nancy, FRA) & Katherine Tuttle (Seattle, USA)

Panelists: Rajiv Agarwal (Indianapolis, USA), Patrick Gee (Chesterfield, USA), Sibylle Hauske (Boehringer Ingelheim, GER), Hiddo Heerspink (Groningen, NED), Meg Jardine (Sydney, AUS), Carolyn Lam (Singapore, SIN), Marc Pfeffer (Boston, USA), Bertram Pitt (Ann Arbor, USA), Krishna Prasad (MRHA, GBR), Peter Rossing (Copenhagen, DEN), Bergur Stefansson (AstraZeneca, SWE), Jeffrey Testani (New Haven, USA), Aliza Thompson (FDA, USA), Christoph Wanner (Würzburg, GER), David Wheeler (London, GBR), Faiez Zannad (Nancy, FRA)

HOW THE HFREF THERAPY LANDSCAPE WILL CHANGE?

Moderators: Barry Greenberg (La Jolla, USA) & Tiny Jaarsma (Linköping, SWE)

Thursday, December 3rd

13:30 – 15:00 Central European Time (CET)



How Important Is Mechanism Of Action?

Are There Elements For Personalized Medicine?

Subodh Verma (Toronto, CAN)

Safety Issues, And How To Accommodate Polypharmacy?

John Cleland (Glasgow, GBR)

Every HF Patient Should Enroll In A HF Disease Management Program!

Tiny Jaarsma (Linköping, SWE)

Day 1 - Thursday, December 3, 2020

The LIVE Forum
Multi-Stakeholder Moderated Debate
HOW THE HFrEF THERAPY LANDSCAPE WILL CHANGE?
Moderators: Barry Greenberg (La Jolla, USA) & Tiny Jaarsma (Linköping, SWE)

Panelists: Stefan Anker (Berlin, GER), Paul W. Armstrong (Alberta, CAN), Javed Butler (Jackson, USA), John Cleland (Glasgow, GBR), Martin Lefkowitz (Novartis, USA), Matias Nordaby (Boehringer Ingelheim, GER), Milton Packer (Dallas, USA), Bertram Pitt (Ann Arbor, USA), Lothar Roessig (Bayer, GER), Salim Shah (Sarfez, USA), James Strait (Merck, USA), Subodh Verma (Toronto, CAN)

THE TRANSFORMATION OF TRIAL CONDUCT POST COVID.
HOW TO KEEP THE BEST?

Moderators: Stefan Anker (Berlin, GER) & Monica Shah (IQVIA, USA)

Thursday, December 3rd

15:00 – 17:30 Central European Time (CET)



DSMCs Issues: How To Ensure Patients Safety In CV Trials During Disrupted Times

Jeffrey Borer (New York, USA)

Moving Toward A Single IRB For All Sites

Yves Rosenberg (NHLBI, USA)

Statistical Issues. How To Deal With Missing Data, Imputed Data, Changes In Data Collections Methods, Drop Outs, Temporary Drug Discontinuation And Potential Loss Of Power?

John Gregson (London, GBR)

Going Forward Peri-To-Post COVID-19. The DCRI Trial Experience

Adrian Hernandez (Durham, USA)

Regulatory COVID19 Guidance Document Review

Charu Gandotra (FDA, USA)

How Industry Trials Adapted During The COVID-19 Crisis?

Monica Shah (IQVIA, USA)

Industry Trials Case-Studies

Elliot Barnathan (JnJ, USA), Antonieta Bomfim Wirtz (Bayer, GER), Narimon Honarpour (Amgen, USA), Laura Mauri (Medtronic, USA)

Patient Viewpoints

Nick Hartshorne-Evans (Pumping Marvellous Foundation, London, GBR), Greg Merritt (Ann Arbor, USA)

The LIVE Forum
Multi-Stakeholder Moderated Debate
THE TRANSFORMATION OF TRIAL CONDUCT POST COVID.
HOW TO KEEP THE BEST?

Moderators: Stefan Anker (Berlin, GER) & Monica Shah (IQVIA, USA)

Panelists: Jodi Akin (Hawthorne Effect, USA), Sadegh Alikhaani (Los Angeles, USA), Elliot Barnathan (JnJ, USA), Antonieta Bomfim Wirtz (Bayer, GER), Jeffrey Borer (New York, USA), Peter Carson (Chapel Hill, USA), Andrew Farb (FDA, USA), Charu Gandotra (FDA, USA), Robert Golub (JAMA, Washington, USA), John Gregson (London, GBR), Penilla Gunther (Stockholm, SWE), Nick Hartshorne-Evans (Pumping Marvellous Foundation, London, GBR), Adrian Hernandez (Durham, USA), Narimon Honarpour (Amgen, USA), Larry Husten (CVCTCardioBrief, New York, USA), John Jarcho (NEJM, Boston, USA), Laura Mauri (Medtronic, USA), Mandeep Mehra (Boston, USA), Greg Merritt (Ann Arbor, USA), Gail Pearson (NHLBI, USA), Yves Rosenberg (NHLBI, USA), Stuart Spencer (The Lancet, London, GBR), Mintu Turakhia (Stanford, USA), Harriette Van Spall (Hamilton, CAN), Bram Zuckerman (FDA, USA)

Day 1 - Thursday, December 3, 2020

NASH AND OBESITY TRIALS Part 1: CHANGING PARADIGM

Moderators: Stephen Harrison (San Antonio, USA) & Arun Sanyal (Richmond, USA)
Thursday, December 3rd
17:30 – 19:30 Central European Time (CET)



NASH, Diabetes And Obesity: Insulin Resistance Driving Increased CV Risk Across The 3 Conditions

Naveed Sattar (Glasgow, GBR)

What NASH Drugs And Trials Are In The Pipeline

Stephen Harrison (San Antonio, USA)

GLP-1 Receptor Agonists Obesity Trials

Benjamin Scirica (Boston, USA)

Is All Obesity The Same? What Phenotypes Are Associated With Cardiovascular Risk?

Barry Borlaug (Minneapolis, USA)

Current NASH Trials Endpoints And Next Steps: Role Of Artificial Intelligence And Noninvasive Tests Moving Forward

Michael Charlton (Chicago, USA)

“Time-Dependent” Outcomes And What End-Points In Future NASH Trials

Muthiah Vaduganathan (Boston, USA)

NASH And Obesity: Evolving Regulatory Guidance On CVOT

Frank Anania (FDA, USA)

The LIVE Forum Multi-Stakeholder Moderated Debate NASH AND OBESITY TRIALS MULTI-STAKEHOLDERS’ MULTI-SPECIALISTS CROSS TALK

Moderators: Stephen Harrison (San Antonio, USA) & Arun Sanyal (Richmond, USA)

Panelists: Frank Anania (FDA, USA), Barry Borlaug (Minneapolis, USA), Manu Chakravarthy (Axcella, USA), Michael Charlton (Chicago, USA), Gad Cotter (Momentum Research, USA), Beth Davison (Momentum Research, USA), Howard Dittrich (Cirius Pharmaceutical, USA), Steve Macari (Poitiers, FRA), Julio Rosenstock (Dallas, USA), Donna Ryan (Baton Rouge, USA), Naveed Sattar (Glasgow, GBR), Benjamin Scirica (Boston, USA), John Sharretts (FDA, USA), Muthiah Vaduganathan (Boston, USA)

NASH AND OBESITY TRIALS Part 2: MULTI STAKEHOLDERS’ FORUM

Moderators: Stephen Harrison (San Antonio, USA), Arun Sanyal (Richmond, USA)
Thursday, December 3rd
20:00 – 21:30 Central European Time (CET)



Statistical Viewpoint

Beth Davison (Momentum Research, USA)

Cardiologist Viewpoint

Muthiah Vaduganathan (Boston, USA)

Diabetologist Viewpoint

Julio Rosenstock (Dallas, USA)

Obesity Specialist Viewpoint

Donna Ryan (Baton Rouge, USA)

Industry Viewpoints

Manu Chakravarthy (Axcella, USA), Gad Cotter (Momentum Research, USA), Howard Dittrich (Cirius Pharmaceutical, USA)

Day 1 - Thursday, December 3, 2020

The LIVE Forum

Multi-Stakeholder Moderated Debate

NASH AND OBESITY TRIALS MULTI-STAKEHOLDERS' MULTI-SPECIALISTS CROSS TALK

Moderators: Stephen Harrison (San Antonio, USA) & Arun Sanyal (Richmond, USA)

Panelists: Frank Anania (FDA, USA), Barry Borlaug (Minneapolis, USA), Manu Chakravarthy (Axcella, USA), Michael Charlton (Chicago, USA), Gad Cotter (Momentum Research, USA), Beth Davison (Momentum Research, USA), Howard Dittrich (Cirius Pharmaceutical, USA), Steve Macari (Poitiers, FRA), Julio Rosenstock (Dallas, USA), Donna Ryan (Baton Rouge, USA), Naveed Sattar (Glasgow, GBR), Benjamin Scirica (Boston, USA), John Sharretts (FDA, USA), Muthiah Vaduganathan (Boston, USA)

iCVCT 1

INTERVENTIONAL CLINICAL TRIALS IN THE TIME OF COVID CHALLENGES FOR DEVICE STUDIES IN INTERVENTIONAL THERAPIES

Moderators: Michael Gibson (Boston, USA) & Roxana Mehran (New York, USA)

Thursday, December 3th

17:30 – 19:30 (Central European Time) CET



Welcome and Introduction

Roxana Mehran & Michael Gibson

Opening Lecture: Keynote

Bram Zuckerman (FDA, USA)

Trialist Perspective

Michael Gibson (Boston, USA)

Industry Perspective

Jennifer Jones (Abbott Vascular, USA)

iCVCT 1

The LIVE Forum

Multi-Stakeholder Moderated Debate

CHALLENGES FOR DEVICE TRIALS IN THE TIME OF COVID QUICK FIX AND ENDURING CHANGES

Moderators: Mike Gibson (Boston, USA) & Roxana Mehran (New York, USA)

Panelists: William Abraham (Columbus, USA), Andrew Farb (FDA, USA), Mayra Guerrero (Rochester, USA), Jennifer Jones (Abbott Vascular, USA), JoAnn Lindenfeld (Nashville, USA), Manuela Negoita (Medtronic, USA), Kartik Sundareswaran (Abbott, USA), Changfu Wu (FDA, USA), Nadim Yared (CVRx, USA), Bram Zuckerman (FDA, USA)

MAKING CV PRECISION MEDICINE BECOME A REALITY

Moderators: Gemma Figtree (Sydney, AUS) & Joseph A Hill (Dallas, USA)

Thursday, December 3th

19:30 – 21:30 Central European Time (CET)



Can A Precision Stratification Approach Increase CV Biotargets Drugability?

Gemma Figtree (Sydney, AUS)

How Can We Improve Our Phenotypic Stratification In Multifaceted CV Disease Trials?

• In Coronary Artery Disease

Charalambos Antoniades (Oxford, GBR)

• In Heart Failure

Joseph A Hill (Dallas, USA)

How Could A Precision Stratification Approach Become More Attractive To Industry For Common CV Diseases Not Just Orphan Diseases?

Bronwyn Kingwell (CSL, AUS), Benoit Tyl (Servier, FRA)

How Would A Precision CV Transformation Influence Regulatory Processes For New Agents?

Robert Califf (Verily, USA)

Day 1 - Thursday, December 3, 2020

The LIVE Forum Multi-Stakeholder Moderated Debate ROADMAP TO CV PRECISION MEDICINE TRIALS

Moderators: Gemma Figtree (Sydney, AUS) & Joseph A Hill (Dallas, USA)

Panelists: Charalambos Antoniades (Oxford, GBR), Agim Beshiri (Abbot Dx, USA), Karine Bourgeois (4TEEN4 Pharmaceuticals GmbH, GER), Robert Califf (Verily, USA), Christopher De Filippi (Washington, USA), Lawrence Fine (NHLBI, USA), Steven Gough (NovoNordisk, DEN), Chris Granger (Durham, USA), Barry Greenberg (La Jolla, USA), Ziad Hijazi (Uppsala, SWE), Bronwyn Kingwell (CSL, AUS), Anissa Lamarque (Olink, FRA), Alexandre Mebazaa (Paris, FRA), Pieter Muntendam (G3Pharmaceuticals, USA), Richard Nkulikiyinka (Bayer AG, GER), Sandra Sanders-Van Wijk (Maastricht, NED), Michele Senni (Bergamo, ITA), Thomas Thuren (Novartis, USA), Benoit Tyl (Servier, FRA), Faiez Zannad (Nancy, FRA), Andre Ziegler (Roche Dx, CHE)

www.globalcvctforum.com

Day 2 - Friday, December 4, 2020

THE VALUE OF BIOMARKERS IN TRIALS

Moderators: Kirkwood Adams (Chapel Hill, USA) & Lawrence Fine (NHLBI, USA)

Friday, December 4th

13:30 – 15:30 Central European Time (CET)



Biomarkers In Primary Prevention Trials

- **Biomarkers As Surrogates For Efficacy In CV Primary Prevention Trials**

Lawrence Fine (NHLBI, USA)

- **Imaging Residual Inflammatory Risk In The Clinical Trials Of The Future**

Charalambos Antoniades (Oxford, GBR)

Biomarker Strategies To Improve Clinical Management

- **Biomarker Phenotyping Of Clinical Heart Failure To Promote Best Use Of Polypharmacy**

Sandra Sanders-van Wijk (Maastricht, NED)

- **hs-Troponin In Ischemic Syndromes**

Christopher deFilippi (Washington, USA)

- **Clinical Value Of Biomarkers In Atrial Fibrillation Prognostic Stratification - Therapy Risk**

Ziad Hijazi (Uppsala, SWE)

Industry Viewpoint

Agim Beshiri (Abbott Dx, USA), Karine Bourgeois (4TEEN4 Pharmaceuticals GmbH, GER)

The LIVE Forum

Multi-Stakeholder Moderated Debate

FUTURE GOALS OF CV BIOMARKER CLINICAL DEVELOPMENT – WHICH WAY FORWARD IN 2021?

Moderators: Kirkwood Adams (Chapel Hill, USA) & Lawrence Fine (NHLBI, USA)

Panelists: Charalambos Antoniades (Oxford, GBR), Agim Beshiri (Abbott Dx, USA), Karine Bourgeois (4TEEN4 Pharmaceuticals GmbH, GER), Christopher deFilippi (Washington, USA), Ziad Hijazi (Uppsala, SWE), Anissa Lamarque (Olink, FRA), Alexandre Mebazaa (Paris, FRA), Sandra Sanders-van Wijk (Maastricht, NED), Faiez Zannad (Nancy, FRA), Andre Ziegler (Roche Dx, CHE)

UNDERSTANDING AND INTERPRETING THE RESULTS OF MINERALOCORTICOID RECEPTOR ANTAGONISTS TRIALS IN DIABETES KIDNEY DISEASE

Moderators: Rajiv Agarwal (Indianapolis, USA) & Meg Jardine (Sydney, AUS)

Friday, December 4th

16:00 – 18:00 Central European Time (CET)



Unmet Needs In Diabetes Cardio-Kidney Disease

Katherine Tuttle (Seattle, USA)

FIDELIO Results

- **FIDELIO-DKD Main Renal Outcomes Results**

Rajiv Agarwal (Indianapolis, USA)

- **FIDELIO-DKD Cardiovascular Outcomes Results**

Gerasimos Filippatos (Athens, GRE)

- **Target Population, To What Patients FIDELIO-DKD Results Are Applicable?**

Peter Rossing (Copenhagen, DEN)

- **Statistical Viewpoint**

David DeMets (Madison, USA)

Day 2 - Friday, December 4, 2020

The LIVE Forum Multi-Stakeholder Moderated Debate UNDERSTANDING THE RESULTS OF FIDELIO-DKD

Moderators: Rajiv Agarwal (Indianapolis, USA) & Meg Jardine (Sydney, AUS)

Panelists: Michel Azizi (Paris, FRA), David DeMets (Madison, USA), Gerasimos Filippatos (Athens, GRE), Amer Joseph (Bayer, GER), Mikhail Kosiborod (Missouri, USA), Richard Nkulikiyinka (Bayer, GER), Bertram Pitt (Ann Arbor, USA), Patrick Rossignol (Nancy, FRA), Peter Rossing (Copenhagen, DEN), Katherine Tuttle (Seattle, USA), Fred Yang (KBP Biosciences, USA), Faiez Zannad (Nancy, FRA)

KEYNOTE LECTURE WHAT CARDIOLOGY WILL LOOK LIKE IN 2028

Eugene Braunwald (Boston, USA)

Friday, December 4th

18:30 – 19:00 Central European Time (CET)



THE FUTURE OF MRA TRIALS IN HYPERTENSION AND CARDIORENAL DISEASE

Moderators: Gerasimos Filippatos (Athens, GRE) & Bertram Pitt (Ann Arbor, USA)

Friday, December 4th

19:00 – 21:30 Central European Time (CET)



Non-Steroidal And New Generation MRAs Esaxerenone, Finerenone, KBP-5074, AZD9977 And Other New Kids On The Block

Michel Azizi (Paris, FRA)

Hypertension Management In Advanced Chronic Kidney Disease. Results Of The BLOCK-CKD Trial

George Bakris (Chicago, USA)

FIDELIO-DKD In The Context Of Non-Steroidal MRA Cardiovascular And Renal Outcome Trials

Patrick Rossignol (Nancy, FRA)

Heart Failure Trials With MRA Therapy

Faiez Zannad (Nancy, FRA)

Future Cardioresenal Trial Opportunities With MRAs. New Target Populations And Trial Designs

Bertram Pitt (Ann Arbor, USA)

Industry Viewpoint

Lothar Roessig (Bayer, GER), Fred Yang (KBP Bioscience, USA),

Regulatory Viewpoint

Giuseppe Rosano (MHRA, London), Norman Stockbridge (FDA, USA)

www.globalcvctforum.com

Day 2 - Friday, December 4, 2020

The LIVE Forum
Multi-Stakeholder Moderated Debate
THE FUTURE OF MRA CARDIORENAL TRIALS AND THERAPY
Moderators: Gerasimos Filippatos (Athens, GRE) & Bertram Pitt (Ann Arbor, USA)

Panelists: Rajiv Agarwal (Indianapolis, USA), Michel Azizi (Paris, FRA), George Bakris (Chicago, USA), David DeMets (Madison, USA), Meg Jardine (Sydney, AUS), Amer Joseph (Bayer, GER), Mikhail Kosiborod (Missouri, USA), Carolyn Lam (Singapore, SIN), Richard Nkulikeyinka (Bayer, GER), Giuseppe Rosano (MHRA, London), Patrick Rossignol (Nancy, FRA), Lothar Roessig (Bayer, GER), Peter Rossing (Copenhagen, DEN), Norman Stockbridge (FDA, USA), Aliza Thompson (FDA, USA), Katherine Tuttle (Seattle, USA), Fred Yang (KBP Biosciences, USA), Faiez Zannad (Nancy, FRA)

European Heart Journal - CVCT-WOMEN AS ONE Joint Session
EVIDENCE GAPS IN WOMEN'S CARDIOVASCULAR HEALTH
Moderators: Gail Pearson (NHLBI, USA) & Lijing Yan (Kunshan, CHN)
Friday, December 4th
13:30 – 15:30 Central European Time (CET)



**Women Patient's Participation
In Cardiovascular Trials**
Lijing Yan (Kunshan, CHN)

The Women Heart Centers Experience
Annabelle Volgman (Chicago, USA)

Do We Need Sex-Specific CV Guidelines
Harriette Van Spall (Hamilton, CAN)

How To Improve Pregnancy And Peripartum Evidence-Based CV Medicine?
Padma Kaul (Edmonton, CAN)

Cardiovascular Safety Of Women Cancer Therapies
Teresa Lopez Fernandez (Madrid, ESP)

Regulatory Viewpoint
Charu Gandotra (FDA, USA)

Diversity In Clinical Trials: Why Data Reporting According To Sex Matters?
Filippo Crea (Eur Heart Journal, ITA)

The LIVE Forum
Multi-Stakeholder Moderated Debate
HOW TO IMPROVE EVIDENCE BASED WOMEN CARDIOVASCULAR HEALTH?
Moderators: Gail Pearson (NHLBI, USA) & Lijing Yan (Kunshan, CHN)

Panelists: Ariel Ash-Shakoor (FDA, USA), Biykem Bozkurt (Houston, USA), Filippo Crea (Eur Heart Journal, ITA), Charu Gandotra (FDA, USA), Martha Gulati (Phoenix, USA), Padma Kaul (Edmonton, CAN), Carolyn Lam (Singapore, SIN), Teresa Lopez Fernandez (Madrid, ESP), Tabassome Simon (Paris, FRA), Harriette Van Spall (Hamilton, CAN), Annabelle Volgman (Chicago, USA), Mary Walsh (Baltimore, USA)

www.globalcvctforum.com

Day 2 - Friday, December 4, 2020

CVCT-WOMEN AS ONE Joint Session HOW TO IMPROVE WOMEN'S LEADERSHIP AS CLINICAL TRIALISTS?

Moderators: Biykem Bozkurt (Houston, USA) & Tabassome Simon (Paris, FRA)

Friday, December 4th

16:00 – 18:30 Central European Time (CET)



The Role Of Professional Societies

- **ACC/AHA**

Biykem Bozkurt (Houston, USA)

- **ESC**

Barbara Casadei (Oxford, GBR)

Global Initiatives To Improve Women Leadership As CV Trialists

- **Asia**

Carolyn Lam (Singapore, SIN)

- **Europe**

Tabassome Simon (Paris, FRA)

- **USA**

Mary Walsh (Baltimore, USA)

- **WomenAsOne advocacy**

Roxana Mehran (New York, USA)

- **Industry Plans**

Brooke Allocco (Boston Scientific, USA)

- **Role Of Social Media**

Martha Gulati (Phoenix, USA)

The LIVE Forum

Multi-Stakeholder Moderated Debate

THE ROADMAP TOWARD WOMEN'S LEADERSHIP AS CLINICAL TRIALISTS

Moderators: Biykem Bozkurt (Houston, USA) & Tabassome Simon (Paris, FRA)

Panelists: Brooke Allocco (Boston Scientific, USA), Antonieta Bomfim Wirtz (Bayer, GER), Barbara Casadei (London, GBR), George Dangas (New York, USA), Thomas Deering (Atlanta, USA), Charu Gandotra (FDA, USA), Bernard Gersh (Rochester, USA), Martha Gulati (Phoenix, USA), Gerhard Hindricks (Leipzig, GER), Padma Kaul (Edmonton, CAN), Carolyn Lam (Singapore, SIN), Anna-Maria Langkilde (AstraZeneca, SWE), Rebecca Ortega (Durham, USA), Gail Pearson (NHLBI, USA), James Revkin (Pfizer, USA), Naveed Sattar (Glasgow, GBR), Monica Shah (IQVIA, USA), Harriette Van Spall (Hamilton, CAN), Annabelle Volgman (Chicago, USA), Mary Walsh (Baltimore, USA)

www.globalcvctforum.com

Day 2 - Friday, December 4, 2020

OPERATIONAL SHIFTS IN TRIAL CONDUCT LESSONS LEARNT FROM THE COVID-19 CRISIS

Moderators: Gail Pearson (NHLBI, USA) & Monica Shah (IQVIA, USA)

Friday, December 4th

19:00 – 21:00 Central European Time (CET)



Adapting Clinical Trials Operations During Health Crisis

• Enrolment Challenges And Participants' Support

Monica Shah (IQVIA, USA)

• Shifting From Clinic Visits To Home-Based Testing, Remote Monitoring And Telemedicine Clinical Trials

Mintu Turakhia (Stanford, USA)

• Home Nursing And Decentralized Follow Up Staff

Jodi Akin (Hawthorne Effect, USA)

• Remote Monitoring And Decentralized Follow Up: How Do We Safely Incorporate Into Trials?

Sadegh Alikhaani (Los Angeles, USA), Penilla Gunther (Stockholm, SWE)

Use Of Public Records And Medico-Administrative Registries To Assess Outcomes In CV Trials

Stefan James (Uppsala, SWE)

Clinical Endpoint Committees Issues. How COVID-19 Events May Influence Endpoint Collection And Adjudication

Peter Carson (Chapel Hill, USA)

The LIVE Forum

Multi-Stakeholder Moderated Debate

OPERATIONAL SHIFTS IN TRIAL CONDUCT LESSONS LEARNT FROM THE COVID-19 CRISIS

Moderators: Gail Pearson (NHLBI, USA) & Monica Shah (IQVIA, USA)

Panelists: Jodi Akin (Hawthorne Effect, USA), Sadegh Alikhaani (Los Angeles, USA), Elliot Barnathan (JnJ, USA), Antonieta Bomfim Wirtz (Bayer, GER), Jeffrey Borer (New York, USA), Peter Carson (Chapel Hill, USA), Saliu Drilon (Philips, USA), Robert Golub (JAMA, Washington, USA), John Gregson (London, GBR), Penilla Gunther (Stockholm, SWE), Nick Hartshorne-Evans (Pumping Marvellous Foundation, London, GBR), Narimon Honarpour (Amgen, USA), Stefan James (Uppsala, SWE), John Jarcho (NEJM, Boston, USA), Mandeep Mehra (Boston, USA), Greg Merritt (Ann Arbor, USA), Stuart Spencer (The Lancet, London, GBR), Mintu Turakhia (Stanford, USA)

HOW WILL THE REMOVAL OF REQUIREMENT FOR CVOT FROM THE 2020 FDA DIABETES GUIDANCE SHAPE THE FUTURE OF TRIAL DESIGN?

Moderators: John Cleland (Glasgow, GBR) & Lynne Stevenson (Nashville, USA)

Friday, December 4th

13:30 – 15:30 Central European Time (CET)



Cardiologist Viewpoint

John Cleland (Glasgow, GBR)

Patients Viewpoint

Jacqueline Alikhaani (Los Angeles, USA)

Industry Viewpoint

Graziella Collu (AstraZeneca, SWE), Waheed Jamal (Boehringer Ingelheim, GER), James Revkin (Pfizer, USA), Jeffrey Riesmeyer (Lilly, USA)

Regulatory Viewpoint

Angeles Alonso (MHRA, GBR)

Day 2 - Friday, December 4, 2020

The LIVE Forum **Multi-Stakeholder Moderated Debate** **INTERPRETING THE RESULTS OF SGLT2 INHIBITORS DIABETES, HF AND CKD TRIALS** Moderators: John Cleland (Glasgow, GBR) & Lynne Stevenson (Nashville, USA)

Panelists: Jacqueline Alikhaani (Los Angeles, USA), Angeles Alonso (MHRA, GBR), Graziella Collu (AstraZeneca, SWE), Hiddo Heerspink (Groningen, NED), Waheed Jamal (Boehringer Ingelheim, GER), Jack Lawrence (Janssen, USA), Steven Nissen (Cleveland, USA), James Revkin (Pfizer, USA), Jeffrey Riesmeyer (Lilly, USA), Julio Rosenstock (Dallas, USA), Ellis Unger (FDA, USA)

EVIDENCE GENERATION IN FOOD AND DIET HEALTH SCIENCE Moderators: Joao Ferreira (Nancy, FRA) & Abhinav Sharma (Montreal, CAN) Friday, December 4th 16:00 – 18:30 Central European Time (CET)



Moving From Empirical To Mechanistically Targeted Active Food Ingredients.

Fibrosis, Galectin 3 And Citrus Pectins
Faiez Zannad (Nancy, FRA)

Plant-Based Alternatives To Animal Products: Potential Health And Environmental Impact
Erin Rees Clayton (Good Food Institute, USA)

Nutraceuticals And Bioactive Food Products: Regulatory Viewpoint
Fred Senatore (FDA, USA)

Barriers To Healthy Diet Implementation : The Role Of Behavioural Science
Estefanía Toledo (Madrid, ESP)

Industry Viewpoint
Pieter Muntendam (G3Pharmaceuticals, USA), Hans Juergen Woerle (Nestlé HealthScience, CHE)

Patients Viewpoint
Denis Janssen (Zuid, NED), Jayna Williams (New Hampshire, USA)

The LIVE Forum **Multi-Stakeholder Moderated Debate** **FOOD AND DIET HEALTH SCIENCE. WHAT EVIDENCE IS NEEDED AND HOW TO GENERATE?** Moderators: Joao Ferreira (Nancy, FRA) & Abhinav Sharma (Montreal, CAN)

Panelists: Thomas Andersson (AstraZeneca, SWE), Nir Barzilai (New York, USA), Adriane Berg (Kinexum, USA), Javed Butler (Jackson, USA), Erin Rees Clayton (Good Food Institute, USA), Susan Ellenberg (Philadelphia, USA), Alexander Fleming (Kinexum, USA), Steven Gough (NovoNordisk, DEN), Larry Husten (CVCTCardioBrief, USA), Denis Janssen (Zuid, NED), Stephen Kritchevsky (Winston-Salem, USA), Pieter Muntendam (G3Pharmaceuticals, USA), Steven Nissen (Cleveland, USA), Donna Ryan (Baton Rouge, USA), Fred Senatore (FDA, USA), Estefanía Toledo (Madrid, ESP), Ellis Unger (FDA, USA), Jayna Williams (New Hampshire, USA), Janet Wittes (Washington, USA), Hans Juergen Woerle (Nestlé HealthScience, CHE), Faiez Zannad (Nancy, FRA)

Day 3 - Saturday, December 5, 2020

UNDERSTANDING THE RESULTS OF SGLT2 INHIBITORS HEART FAILURE TRIALS

Moderators: Milton Packer (Dallas, USA) & Ileana Piña (Detroit, USA)

Saturday, December 5th

13:30 – 15:30 Central European Time (CET)



SGLT2i HFrEF Trials Main Results And Trial Level Meta-Analysis

Faiez Zannad (Nancy, FRA)

Focus On Hard Outcomes

Stefan Anker (Berlin, GER)

Quality Of Life Outcomes

Javed Butler (Jackson, USA)

Renal And Cardio-Renal Considerations

Joao Ferreira (Nancy, FRA)

Safety Considerations

Gerasimos Filippatos (Athens, GRE)

Mechanistic Insight

Milton Packer (Dallas, USA)

Industry viewpoint

Anna-Maria Langkilde (Astrazeneca, SWE)

Statistical Viewpoint

Stuart Pocock (London, GBR)

The LIVE Forum

Multi-Stakeholder Moderated Debate

UNDERSTANDING THE RESULTS OF SGLT2 INHIBITORS HEART FAILURE TRIALS

Moderators: Milton Packer (Dallas, USA) & Ileana Piña (Detroit, USA)

Panelists: Rajiv Agarwal (Indianapolis, USA), Jacqueline Alikhaani (Los Angeles, USA), Angeles Alonso (MHRA, GBR), Thomas Anderson (AstraZeneca, SWE), Stefan Anker (Berlin, GER), Javed Butler (Jackson, USA), David DeMets (Madison, USA), Joao Ferreira (Nancy, FRA), Gerasimos Filippatos (Athens, GRE), Meg Jardine (Sydney, AUS), Mikhail Kosiborod (Missouri, USA), Anna-Maria Langkilde (Astrazeneca, SWE), Richard Nkulikiyinka (Bayer), Bertram Pitt (Ann Arbor, USA), Stuart Pocock (London, GBR), Jeffrey Riesmeyer (Lilly, USA), Peter Rossing (Copenhagen, DEN), Michele Senni (Bergamo, ITA), Benoit Tyl (Servier, FRA), Ola Vedin (Boehringer Ingelheim, GER), Faiez Zannad (Nancy, FRA)

PATIENT ENGAGEMENT IS MORE THAN A CATCHPHRASE: ONE PATIENT DOES NOT ENGAGEMENT MAKE

Moderators: Cynthia Chauhan (Wichita, USA) & Penilla Gunther (Stockholm, SWE)

Saturday, December 5th

16:00 – 18:00 Central European Time (CET)



Partners In Trial Development: How Can We Incorporate Patient Engagement From Conceptualization Through Completion Of Every Trial?

Jeff Sloan (Rochester, USA), Jayna Williams (New Hampshire, USA)

Quality Of Life Indexes: Do QoL Indexes Really Inform And Improve Trial Outcomes? Do Trialists Use The Information Gathered To Improve Patient Well-Being?

Jacqueline Alikhaani (Los Angeles, USA), Marietta Verbakel (Nijmegen, NED)

Translating And Communicating Trials To Patients: How Do We Entice Patients To Choose And Participate In Trials? How Do We Make Sharing Results Mandatory?

Marc Bains (Vancouver, CAN), Robin Martinez (Denver, USA)

Diversity And Equal Access In Trial Participation: If A Trial Isn't Diverse And Equally Accessible How Can It Possibly Address Its Issue Effectively?

Patrick Gee (Chesterfield, USA), Wanda F Moore (Tucson, USA)

Day 3 - Saturday, December 5, 2020

The LIVE Forum Multi-Stakeholder Moderated Debate **PATIENT TRIALISTS AND CLINICIAN TRIALISTS DIALOGUE** Moderators: Cynthia Chauhan (Wichita, USA) & Penilla Gunther (Stockholm, SWE)

Panelists: Jacqueline Alikhaani (Los Angeles, USA), Sadegh Alikhaani (Los Angeles, USA), Marc Bains (Vancouver, CAN), Patrick Gee (Chesterfield, USA), Martha Gulati (Phoenix, USA), Nick Hartshorne-Evans (Pumping Marvellous Foundation, London, GBR), Larry Husten (CVCTCardioBrief, USA), Tiny Jaarsma (Linköping, SWE), Denis Janssen (Zuid, NED), Tamara Krcmar (Servier, FRA), Harlan Krumholz (New Haven, USA), Steve Macari (Poitiers, FRA), Robin Martinez (Denver, USA), Greg Merritt (Ann Arbor, USA), Wanda F Moore (Tucson, USA), Bray Patrick-Lake (Durham, USA), Ileana Piña (Detroit, USA), Monica Shah (IQVIA, USA), Jeff Sloan (Rochester, USA), Marjorie Smelstor (Kansas City, USA), John Spertus (Kansas City, USA), Aliza Thompson (FDA, USA), Marietta Verbakel (Nijmegen, NED), Jayna Williams (New Hampshire, USA)

PATIENT REPORTED OUTCOMES VALIDITY AND VALUATION Moderators: John Spertus (Kansas City, USA) & Harriette Van Spall (Hamilton, CAN) Saturday, December 5th 18:30 – 21:00 Central European Time (CET)



Methodological Issues

- **How To Design Clinical Trials With Pros From Patient Selection To Timing Of Assessments To Analysis?**
Adrian Hernandez (Durham, USA)
- **Pros In Composite Endpoints. Can We Combine Soft And Hard Outcomes?**
Suzanne Arnold (Kansas City, USA)
- **Validation With “Objective Metrics” Acquired Through Mobile Health Technologies METEORIC**
Michael Felker (Durham, USA)
- **Can Pros Be Valid In Unblinded Trials (ISCHEMIA Vs. ORBIT, Device Trials And Surgery)**
Daniel Mark (Durham, USA)

Clinical Significance

- **How To Convert The Mean Effect In 100-Point Scales To Clinically-Interpretable Measures Of Benefit?**
John Spertus (Kansas City, USA)
- **Patient Viewpoint**
Jeff Sloan (Rochester, USA), Patricia Vlasman (Amsterdam, NED)

Industry Viewpoint

Luke Bamber (Bayer, GER)

Approvability Of Pros. Regulatory Viewpoint

Elektra Papadopoulos (FDA, USA)

The LIVE Forum Multi-Stakeholder Moderated Debate **PATIENT REPORTED OUTCOMES VALIDITY AND VALUATION** Moderators: John Spertus (Kansas City, USA), Harriette Van Spall (Hamilton, CAN)

Panelists: Suzanne Arnold (Kansas City, USA), Luke Bamber (Bayer, GER), Cynthia Chauhan (Wichita, USA), David DeMets (Madison, USA), Michael Felker (Durham, USA), Nick Hartshorne-Evans (Pumping Marvellous Foundation, GBR), Adrian Hernandez (Durham, USA), Robert Kazmierski (FDA, USA), Daniel Mark (Durham, USA), Elektra Papadopoulos (FDA, USA), Ileana Piña (Detroit, USA), Jeff Sloan (Rochester, USA), Patricia Vlasman (Amsterdam, NED), Emmanouil Zouridakis (MHRA, GBR)

Day 3 - Saturday, December 5, 2020

ATHEROSCLEROSIS TRIALS

PART 1: TRADITIONAL TARGETS AND INNOVATIVE APPROACHES

Moderators: Wolfgang Koenig (Munich, GER) & Paul Ridker (Boston, USA)

Saturday, December 5th

13:30 – 16:00 Central European Time (CET)



From Traditional Pharmacology To Nucleic-Acid-Based Therapies For Cardiovascular Diseases

Ulf Landmesser (Berlin, GER)

Inclisiran In The Treatment Of Hypercholesterolemia – A Game Changer?

- Mechanism Of RNA Interference – Focus On Inclisiran

Ulf Landmesser (Berlin, GER)

- Trials Of Inclisiran In Patients With Elevated LDL Cholesterol

Kausik Ray (London, GBR)

Ongoing And Future Cardiovascular Outcome Trials

- ORION IV

David Preiss (Oxford, GBR)

- VESALIUS-CV

Robert Giugliano (Boston, USA)

Putting Inclisiran Into Perspective (PCSK9 Antibodies, Bempedoic Acid, Statins)

Wolfgang Koenig (Munich, GER)

Fish Oil, EPA, DHA, Triglycerides, And Other Lessons After REDUCE-IT And STRENGTH.

Deepak Bhatt (Boston, USA), Steven Nissen (Cleveland, USA)

Dal-GenE: A Pharmacogenetic Trial To Reduce Atherosclerotic Events

Jean-Claude Tardif (Montreal, CAN)

What And How Should Be The Next Atherosclerosis Trials

Peter Libby (Boston, USA)

Women In Primary And Secondary CV Prevention Trials

Erin Michos (Baltimore, USA)

The LIVE Forum

Multi-Stakeholder Moderated Debate

UNDERSTANDING AND INTERPRETING ATHEROSCLEROSIS TRIALS

Moderators: Wolfgang Koenig (Munich, GER) & Paul Ridker (Boston, USA)

Panelists: Deepak Bhatt (Boston, USA), Jan H. Cornel (Nijmegen, NED), Michael Davidson (Corvidia Therapeutics, USA), Robert Giugliano (Boston, USA), Craig Granowitz (Amarin, USA), Hovingh Kees (NovoNordisk, DEN), Ulf Landmesser (Berlin, GER), Peter Libby (Boston, USA), Douglas Mann (Saint Louis, USA), Erin Michos (Baltimore, USA), Wanda F Moore (Tucson, USA), Steven Nissen (Cleveland, USA), Krishna Prasad (MHRA, GBR), David Preiss (Oxford, GBR), Kausik Ray (London, GBR), John Sharretts (FDA, USA), Jean-Claude Tardif (Montreal, CAN), Thomas Thuren (Novartis, USA)

Day 3 - Saturday, December 5, 2020

ATHEROSCLEROSIS TRIALS

PART 2: HOW CLINICAL TRIALS HELP PROGRESSING THE INFLAMMATION HYPOTHESIS IN CVD?

Moderators: Peter Libby (Boston, USA) & Jean-Claude Tardif (Montreal, CAN)

Saturday, December 5th

16:00 – 18:00 Central European Time (CET)



Inflammation Biotargets For Current And Future Atherosclerosis And CVD Clinical Trials

Peter Libby (Boston, USA)

Lessons Learnt From Large CVOTs So Far (CANTOS, CIRT, and COLCOT)

Jean-Claude Tardif (Montreal, CAN)

Residual Inflammatory Risk: Results From LoDoCo2

Jan H. Cornel (Nijmegen, NED)

Targeting The IL-6 Pathway. RESCUE And What Is Next?

Paul Ridker (Boston, USA)

Targeting Inflammation In Heart Failure

Douglas Mann (Saint Louis, USA)

Design and statistical issues in atherosclerosis trials

Jan Tijssen (Naarden, NED)

Industry viewpoint

Hovingh Kees (NovoNordisk, USA), Thomas Thuren (Novartis, USA)

The LIVE Forum

Multi-Stakeholder Moderated Debate

DESIGN ISSUES IN CVD INFLAMMATION CLINICAL TRIALS

Moderators: Peter Libby (Boston, USA) & Jean-Claude Tardif (Montreal, CAN)

Panelists: Deepak Bhatt (Boston, USA), Jan H. Cornel (Nijmegen, NED), Michael Davidson (Corvidia Therapeutics, USA), Robert Giugliano (Boston, USA), Craig Granowitz (Amarin, USA), Hovingh Kees (NovoNordisk, DEN), Wolfgang Koenig (Munich, GER), Ulf Landmesser (Berlin, GER), Douglas Mann (Saint Louis, USA), Erin Michos (Baltimore, USA), Krishna Prasad (MHRA, GBR), David Preiss (Oxford, GBR), Paul Ridker (Boston, USA), Fred Senatore (FDA, USA), Jan Tijssen (Naarden, NED), Thomas Thuren (Novartis, USA)

ATHEROSCLEROSIS TRIALS

PART 3: APPROVAL, IMPLEMENTATION AND REIMBURSEMENT CHALLENGES

Moderators: David Preiss (Oxford, GBR) & Jean-Claude Tardif (Montreal, CAN)

Saturday, December 5th

18:30 – 20:30 Central European Time



Industry Viewpoint

Michael Davidson (Corvidia Therapeutics, USA),
Craig Granowitz (Amarin, USA), Thomas Thuren (Novartis, USA)

Regulatory Viewpoint

Krishna Prasad (MHRA, GBR), John Sharretts (FDA, USA)

Patient Viewpoint

Marietta Verbakel (Nijmegen, NED)

Day 3 - Saturday, December 5, 2020

The LIVE Forum
Multi-Stakeholder Moderated Debate
APPROVAL, IMPLEMENTATION AND REIMBURSEMENT CHALLENGES
Moderators: David Preiss (Oxford, GBR) & Jean-Claude Tardif (Montreal, CAN)

Panelists: Deepak Bhatt (Boston, USA), Jan H. Cornel (Nijmegen, NED), Michael Davidson (Corvidia Therapeutics, USA), Craig Granowitz (Amarin, USA), Hovingh Kees (NovoNordisk, DEN), Wolfgang Koenig (Munich, GER), Ulf Landmesser (Berlin, GER), Peter Libby (Boston, USA), Douglas Mann (Saint Louis, USA), Erin Michos (Baltimore, USA), Wanda F Moore (Tucson, USA), Krishna Prasad (MHRA, GBR), Paul Ridker (Boston, USA), John Sharretts (FDA, USA), Thomas Thuren (Novartis, USA), Marietta Verbakel (Nijmegen, NED)

iCVCT 2
TRIALS AND TRIBULATIONS ON HIGH BLEEDING RISK PATIENTS
Moderators: Michael Gibson (Boston, USA) & Roxana Mehran (New York, USA)
Saturday, December 5th
13:30 – 15:30 Central European Time (CET)



Assessing Peri-Operative Bleeding Risk

Dominick Angiolillo (Jacksonville, USA)

Case Presentation: Patient With AF, One Week After Complex PCI, Has A Fall With A Fractured Hip, On Full Dose Ticagrelor+ Apixaban

Davide Cao (New York, USA)

Unmet Need For The Prevention/Treatment Of Bleeding In Patients On Antithrombotic Therapy And Current Treatment Strategies

Davide Capodanno (Catania, ITA)

Emergent Antithrombotic Drug Removal Experience With Cytosorb In Real Life Cardiac Surgery

Michael Schmoeckel (Asklepios, GER)

Balancing Ischemia And Bleeding - How Do You Design Trials And Choose Endpoints

Dominick Angiolillo (Jacksonville, USA)

Bleeding Prevention/Antidote Trials. Methodological And Statistical Viewpoint

John Gregson (London, GBR)

Industry Viewpoint

Efthymios Deliargyris (Cytosorbents, USA), Martin Unverdorben (Daiichi-Sankyo, USA)

Regulatory Viewpoint

Adrian Magee (FDA, USA), Fred Senatore (FDA, USA)

iCVCT 2
The LIVE Forum
Multi-Stakeholder Moderated Debate
DESIGN AND ENDPOINT DEFINITION IN BLEEDING TRIALS
Moderators: Michael Gibson (Boston, USA) & Roxana Mehran (New York, USA)

Panelists: Dominick Angiolillo (Jacksonville, USA), Davide Cao (New York, USA), Davide Capodanno (Catania, ITA), Efthymios Deliargyris (Cytosorbents, USA), John Gregson (London, GBR), Adrian Magee (FDA, USA), Michael Schmoeckel (Asklepios, GER), Fred Senatore (FDA, USA), William Smith (Alexion, USA), Martin Unverdorben (Daiichi Sankyo, USA)

www.globalcvctforum.com

Day 3 - Saturday, December 5, 2020

MECHANISTICALLY TARGETED THERAPY IN CARDIOMYOPATHIES.

Moderators: Iacopo Olivotto (Florence, ITA) & Sanjiv Shah (Chicago, USA)

Saturday, December 5th

16:00 – 18:00 Central European Time (CET)



Precision Medicine Approach To NHCM, OHCM, And HFpEF

Sanjiv Shah (Chicago, USA)

Therapeutic Options And Future Opportunities In Cardiomyopathy

Carolyn Ho (Boston, USA), Marty Maron (Boston, USA)

Mavacamten Obstructive Hypertrophic Cardiomyopathy Pre-Approval Trial EXPLORER-HCM

Dan Jacoby (New Haven, USA), Iacopo Olivotto (Florence, ITA)

Therapeutic Options Preventing Diabetic Cardiomyopathy. ARISE-HF.

Faiez Zannad (Nancy, FRA)

Targeted Therapeutics For Transthyretin Cardiac Amyloidosis

Thibaud Damy (Paris, FRA)

The LIVE Forum

Multi-Stakeholder Moderated Debate

CURRENT AND FUTURE MECHANISTIC TARGETS IN CARDIOMYOPATHIES

Moderators: Iacopo Olivotto (Florence, ITA) & Sanjiv Shah (Chicago, USA)

16:00 – 18:00 Central European Time (CET)

Panelists: Stefan Anker (Berlin, GER), Daniel Burkhardt (Cardiovascular Research Foundation, USA), Martin Cowie (Imperial College London, GBR), Thibaud Damy (Paris, FRA), Joao Ferreira (Nancy, FRA), Carolyn Ho (Boston, USA), Dan Jacoby (New Haven, USA), JoAnn Lindenfeld (Nashville, USA), Fady Malik (Cytokinetics, USA), Marty Maron (Boston, USA), Riccardo Perfetti (Applied Therapeutics, USA), Lisa Salberg (HCMA, USA), Scott Solomon (Boston, USA), Kenneth Stein (Boston Scientific, USA), Nadim Yared (CVRx, USA), Faiez Zannad (Nancy, FRA), Bram Zuckerman (FDA, USA)

PATH TO APPROVAL AND IMPLEMENTATION OF CARDIOMYOPATHIES DRUG

Moderators: Martin Cowie (Imperial College London, GBR) & Scott Solomon (Boston, USA)

Saturday, December 5th

18:30 – 20:30 Central European Time (CET)



Regulatory Path To Approval For Cardiomyopathies Drug Approval

Preston Dunnmon (FDA, USA)

Payers Viewpoints

Martin Cowie (Imperial College London, GBR)

Industry Viewpoint

Fady Malik (Cytokinetics, USA)

Patient Viewpoint

Lisa Salberg (HCMA, USA), Juddson Rupp (Charlotte, USA)

www.globalcvctforum.com

DAY 3 - SATURDAY, DECEMBER 5, 2020

The LIVE Forum
Multi-Stakeholder Moderated Debate
PATH TO APPROVAL AND IMPLEMENTATION OF CARDIOMYOPATHIES DRUG
Moderators: Martin Cowie (London, GBR) & Scott Solomon (Boston, USA)

Panelists: Stefan Anker (Berlin, GER), Daniel Burkhoff (Cardiovascular Research Foundation, USA), Thibaud Damy (Paris, FRA), Preston Dunnmon (FDA, USA), Jay Edelberg (BMS, USA), Joao Ferreira (Nancy, FRA), Gerasimos Filippatos (Athens, GRE), Barry Greenberg (La Jolla, USA), Carolyn Ho (Boston, USA), JoAnn Lindenfeld (Nashville, USA), Fady Malik (Cytokinetics, USA), Marty Maron (Boston, USA), Iacopo Olivetto (Florence, ITA), Juddson Rupp (Milestone Pharmaceuticals, USA), Lisa Salberg (HCMA, USA), Sanjiv Shah (Chicago, USA), Kenneth Stein (Boston Scientific, USA), Nadim Yared (CVRx, USA), Faiez Zannad (Nancy, FRA)

www.globalcvctforum.com

Day 4 - Sunday, December 6, 2020

iCVCT 3

MITRAL AND TRICUSPID VALVE DEVICES TRIALS

Moderators: Mayra Guerrero (Rochester, USA) & Changfu Wu (FDA, USA)

Sunday, December 6th

13:30 – 15:00 Central European Time (CET)



Pivotal Transcatheter FMR Device Trials:

What have we learned after COAPT and MITRA-FR?

Mayra Guerrero (Rochester, USA)

Transcatheter Tricuspid Valve Repair and Replacement Trials: The Not So Forgotten Valve.

Rebecca Hahn (New York, USA)

Transcatheter Mitral and Tricuspid Valve Repair and Replacement: Regulatory Considerations

Mauro Moscucci (FDA, USA)

Industry Viewpoint

Jeffrey Popma (Medtronic, USA), Kartik Sundareswaran (Abbott, USA)

iCVCT

The LIVE Forum

Multi-Stakeholders Moderated debate

EVOLVING REGULATORY CONSIDERATIONS FOR MITRAL AND TRICUSPID VALVE DEVICES

Moderators: Mayra Guerrero (Rochester, USA) & Changfu Wu (FDA, USA)

Panelists: Jeffrey Borer (New York, USA), Rebecca Hahn (New York, USA), Michael Mack (Plano, USA), Mauro Moscucci (FDA, USA), Jeffrey Popma (Medtronic, USA), Jaime Raben (FDA, USA), Kartik Sundareswaran (Abbott, USA)

iCVCT 4

CORONARY INTERVENTION TRIALS

COMPLEX PATIENTS- COMPLEX LESIONS TRIALS

Moderators: George Dangas (New York, USA) & Michael Gibson (Boston, USA)

Sunday, December 6th

15:30 – 17:30 Central European Time (CET)



Left Main Coronary Disease Trials:

Close to Consensus?

Bernard Gersh (Rochester, USA)

Left Main PCI v. CABG

Roxana Mehran (New York, USA)

How has ISCHEMIA impacted the field?

Sripal Bangalore (New York, USA)

Peri-procedural MI: How important is it?

Sunil Rao (Durham, USA)

Hemodynamic Support: What evidence do we need?

George Dangas (New York, USA), Holger Thiele (Leipzig, GER)

Industry viewpoint

Chuck Simonton (Abiomed, USA)

Regulatory viewpoint

Lydia Glaw (FDA, USA)

Day 4 - Sunday, December 6, 2020

iCVCT
The LIVE Forum
Multi-Stakeholder Moderated Debate
CORONARY INTERVENTION TRIALS
COMPLEX PATIENTS- COMPLEX LESIONS

Moderators: George Dangas (New York, USA) & Michael Gibson (Boston, USA)

Panelists: Sripal Bangalore (New York, USA), Bernard Gersh (Rochester, USA), Lydia Glaw (FDA, USA), Roxana Mehran (New York, USA), Mauro Moscucci (FDA, USA), Sunil Rao (Durham, USA), Yves Rosenberg (NHLBI, USA), Chuck Simonto, (Abiomed, USA), Marjorie Smelstor (Kansas City, USA), Holger Thiele (Leipzig, GER), Stephan Windecker (Bern, CHE)

iCVCT 5
DAPT CONSIDERATIONS IN PATIENTS POST PCI TRIALS
Moderators: Davide Capodanno (Catania, ITA) & Sunil Rao (Durham, USA)
Sunday December 6th
18:00 – 20:00 Central European Time (CET)



How do you define a HBR patient?

Davide Capodanno (Catania, ITA)

AF and PCI: Now what?

Michael Gibson (Boston, USA)

P2Y12 monotherapy

• Need more data

Deepak Bhatt (Boston, USA)

• Default Therapy for Most

Dominick Angiolillo (Jacksonville, USA)

Industry viewpoint

Martin Unverdorben (Daiichi Sankyo, USA)

Regulatory viewpoint

Adrian Magee (FDA, CDRH, USA)

iCVCT
The LIVE Forum
Moderated Multi-Stake Holders debate
DAPT CONSIDERATIONS IN PATIENTS POST PCI TRIALS
Moderators: Davide Capodanno (Catania, ITA) & Sunil Rao (Durham, USA)

Panelists: Dominick Angiolillo (Jacksonville, USA), Deepak Bhatt (Boston, USA), Davide Capodanno (Catania, ITA), Michael Gibson (Boston, USA), Adrian Magee (FDA, CDRH, USA), Martin Unverdorben (Daiichi Sankyo, USA), Stephan Windecker (Bern, CHE)

www.globalcvctforum.com

Day 4 - Sunday, December 6, 2020

"NULLIUS IN VERBA"

THE CRISIS OF THE EXPERIMENTAL PARADIGM DURING THE COVID-19 PANDEMIC

Moderators: Joao Ferreira (Nancy, FRA) & Murray Epstein (Miami, USA)

Sunday, December 6th

13:30 – 15:30 Central European Time (CET)



The Failure Of The Clinical Trial Enterprise

Robert Califf (Verily, USA)

The NIH Perspective

Michael Lauer (NIH, USA)

The Role Of Major Medical Journals And Editorial Oversight

Joseph Alpert (American J Medicine, Tucson, USA)

Stuart Spencer (The Lancet, London, GBR)

John Jarcho (NEJM, Boston, USA)

Robert Golub (JAMA, Washington, USA)

Real World, Registry And Big Data - How Would I Do Differently If I Had To Do It Again?

Mandeep Mehra (Boston, USA)

Media And The Propagation Of Alternative Facts

Larry Husten (CVCTCardioBrief, USA)

Regulatory Viewpoint

Ellis Unger (FDA, USA)

The LIVE Forum

Multi-Stakeholder Moderated Debate

"NULLIUS IN VERBA"

THE CRISIS OF THE EXPERIMENTAL PARADIGM DURING THE COVID-19 PANDEMIC

Moderators: Joao Ferreira (Nancy, FRA) & Murray Epstein (Miami, USA)

Panelists: Jodi Akin (Hawthorne Effect, USA), Sadegh Alikhaani (Los Angeles, USA), Joseph Alpert (American J Medicine, Tucson, USA), Elliot Barnathan (Johnson & Johnson, USA), Antonieta Bomfim Wirtz (Bayer, GER), Robert Califf (Verily, USA), Peter Carson (Chapel Hill, USA), John Gregson (London, GBR), Robert Golub (JAMA, Washington, USA), Martha Gulati (Phoenix, USA), Penilla Gunther (Stockholm, SWE), Nick Hartshorne-Evans (Pumping Marvellous Foundation, GBR), Larry Husten (CVCTCardioBrief, USA), Stefan James (Uppsala, SWE), John Jarcho (NEJM, Boston, USA), Michael Lauer (NIH, USA), Mandeep Mehra (Boston, USA), Monica Shah (IQVIA, USA), Stuart Spencer (The Lancet, London, GBR), Mintu Turakhia (Stanford, USA), Ellis Unger (FDA, USA)

TARGETING THE VESSELS AND THE HEART

ORAL SOLUBLE GUANYLATE CYCLASE STIMULATOR (VERICIGUAT) AND CARDIAC MYOSIN ACTIVATOR (OMECAMTIV MECARBIL)

Moderators: Barbara Casadei (Oxford, GBR) & Harriette Van Spall (Hamilton, CAN)

Sunday, December 6th

VICTORIA Main Results

Paul W. Armstrong (Alberta, CAN)

GALACTIC Main Results

John Teerlink (San Francisco, USA)

Target Populations - How Severe Is Severe HF?

Javed Butler (Jackson, USA)

Balancing Hard Outcomes And Quality Of Life Outcomes

Ileana Piña (Detroit, USA)

Mechanistic Insights

Fady Malik (Cytokinetics, USA), Burkert Pieske (Berlin, GER)

Statistical Considerations

David DeMets (Madison, USA)

Day 4 - Sunday, December 6, 2020

The LIVE Forum Multi-Stakeholder Moderated Debate VICTORIA AND GALACTIC INTO CONTEXT

Moderators: Barbara Casadei (Oxford, GBR) & Harriette Van Spall (Hamilton, CAN)

Panelists: William Abraham (Columbus, USA), Stefan Anker (Berlin, GER), Paul W. Armstrong (Alberta, CAN), Daniel Burkhoff (Cardiovascular Research Foundation, USA), Javed Butler (Jackson, USA), David DeMets (Madison, USA), Preston Dunnmon (FDA, USA), Irina Elyubaeva (Servier, FRA), Joao Ferreira (Nancy, FRA), Gerasimos Filippatos (Athens, GRE), Adrian Hernandez (Durham, USA), Carolyn Ho (Boston, USA), Narimon Honarpour (Amgen, USA), Christopher Kurtz (Amgen, USA), JoAnn Lindenfeld (Nashville, USA), Fady Malik (Cytokinetics, USA), Marty Maron (Boston, USA), Iacopo Olivetto (Florence, ITA), Milton Packer (Dallas, USA), Mahesh Patel (MSD, USA), Riccardo Perfetti (Applied therapeutics, USA), Burkert Pieske (Berlin, GER), Ileana Piña (Detroit, USA), Stuart Pocock (London, GBR), Piotr Ponikowski (Wroclaw, POL), Lothar Roessig (Bayer, GER), Michele Senni (Bergamo, ITA), Sanjiv Shah (Chicago, USA), Scott Solomon (Boston, USA), Kenneth Stein (Boston Scientific, USA), John Teerlink (San Francisco, USA), Claire Varin (Servier, FRA), Faiez Zannad (Nancy, FRA)

CKD AND CARDIO-KIDNEY TRIALS SEEING THE FOREST FOR THE TREES

Moderators: Carolyn Lam (Singapore, SIN) & Marc Pfeffer (Boston, USA)

Sunday, December 6th

18:00 – 20:30 Central European Time (CET)



Multi-Stakeholder Viewpoints

- **Statistician Viewpoint**

Stuart Pocock (London, GBR)

- **Industry Viewpoints**

Thomas Idorn (NovoNordisk, USA), Richard Nkuliyyinka (Bayer, GER), Jerome Rossert (Astrazeneca, SWE),

- **Regulatory Viewpoint**

Peter Mol (EMA, NED)

- **Clinician Viewpoints**

- **Nephrologist**

Sankar Navaneethan (Houston, USA)

- **Cardiologist**

Marc Pfeffer (Boston, USA)

- **Diabetologist**

Peter Rossing (Copenhagen, DEN)

- **Patient Viewpoints**

Cynthia Chauhan (Wichita, USA), Patrick Gee (Chesterfield, USA)

The LIVE Forum Multi-Stakeholder Moderated Debate APPROVABILITY, REIMBURSEMENT AND FUTURE IMPLEMENTATION IN CLINICAL PRACTICE OF THE RESULTS OF CKD AND CARDIO-KIDNEY TRIALS

Moderators : Carolyn Lam (Singapore,SIN) & Marc Pfeffer (Boston, USA)

Panelists: Rajiv Agarwal (Indianapolis, USA), Michel Azizi (Paris, FRA), Florian Baeres (NovoNordisk, DEN), Cynthia Chauhan (Wichita, USA), David DeMets (Madison, USA), Gerasimos Filippatos (Athens, GRE), Patrick Gee (Chesterfield, USA), Hiddo Heerspink (Groningen, NED), Meg Jardine (Sydney, AUS), Mikhail Kosiborod (Missouri, USA), Peter Mol (EMA, NED), Sankar Navaneethan (Houston, USA), Richard Nkuliyyinka (Bayer, GER), Bertram Pitt (Ann Arbor, USA), Stuart Pocock (London, GBR), Patrick Rossignol (Nancy, FRA), Jerome Rossert (Astrazeneca, SWE), Peter Rossing (Copenhagen, DEN), Jeffrey Testani (New Haven, USA), Aliza Thompson (FDA, USA), Katherine Tuttle (Seattle, USA), Christoph Wanner (Wursburg, GER), David Wheeler (London, GBR), Fred Yang (KBP Biosciences, USA), Faiez Zannad (Nancy, FRA)

Day 4 - Sunday, December 6, 2020

iCVCT 6

BREAKTHROUGH HEART FAILURE DEVICES

Moderators: Nicole Ibrahim (FDA, USA) & JoAnn Lindenfeld (Nashville, USA)

Sunday, December 6th

13:30 – 15:30 Central European Time (CET)



Controlled Trials for Heart Failure Devices Experimenting The FDA Expedited Access Pathway

William Abraham (Columbus, USA)

Remote Monitoring Devices In Heart Failure

Adrian Hernandez (Durham, USA)

Industry Viewpoint

Daniel Burkhoff (Cardiovascular Research Foundation, USA), Kenneth Stein (Boston Scientific, USA)

Devices For Heart Failure: FDA Perspectives On Trial Designs And Endpoints

Meir Shinnar (FDA, USA)

iCVCT

The LIVE Forum

Multi-Stakeholder Moderated Debate

REGULATORY, CLINICAL, AND IMPLEMENTATION CHALLENGES FOR BREAKTHROUGH HEART FAILURE DEVICES

Moderators: Nicole Ibrahim (FDA, USA) & JoAnn Lindenfeld (Nashville, USA)

Panelists: William Abraham (Columbus, USA), Stefan Anker (Berlin, GER), Daniel Burkhoff (Cardiovascular Research Foundation, USA), John Cleland (Glasgow, GBR), Adrian Hernandez (Durham, USA), Navin Kapur (Boston, USA), JoAnn Lindenfeld (Nashville, USA), Milton Packer (Dallas, USA), Mahesh Patel (MSD, USA), Ileana Piña (Detroit, USA), Piotr Ponikowski (Wroclaw, POL), Meir Shinnar (FDA, USA), Kenneth Stein (Boston Scientific, USA), Benoit Tyl (Servier, FRA), Faiez Zannad (Nancy, FRA), Bram Zuckerman (FDA, USA)

INCREASING HEALTHSPAN

THE NEXT FRONTIER FOR CLINICAL TRIALISTS

Moderators: Alexander Fleming (Kinexum, USA) & Andrea Maier (Melbourne, AUS)

Sunday December 6th, 2020

15:30 – 17:30 Central Eastern Time (CET)



Geroscience, An Actionable Target: Increasing Healthspan

Nir Barzilai (New York, USA)

Overview Of The Gero-Interventions Pipeline

Luigi Ferrucci (NIH, USA)

Healthspan Composite Primary Endpoint—Statistical Considerations

Stephen Kritchevsky (Winston-Salem, USA)

The Geroscience Hypothesis, Healthspan, and The Heart

Majd AlGhatrif (NIH, USA)

Geroscience, Ready For Clinical Trial Prime Time?

Mehmood Khan (Life Biosciences, USA)

Regulatory Considerations For Healthspan Trials and Indications

Maciej Kostrubiec (EMA, POL), Lisa Yanoff (FDA, USA)

Day 4 - Sunday, December 6, 2020

The LIVE Forum **Multi-Stakeholder Moderated Debate** **MIGHT INCREASING HEALTHSPAN BECOME AN APPROVABLE INDICATION?**

Moderators: Alexander Fleming (Kinexum, USA) & Andrea Maier (Melbourne, AUS)

Panelists: Majd AlGhatrif (NIH, USA), Nir Barzilai (New York, USA), Adriane Berg (Kinexum, USA), Robert Califf (Verily, USA), Susan Ellenberg (Philadelphia, USA), Luigi Ferrucci (NIH, USA), Steven Gough (NovoNordisk, DEN), Martha Gulati (Phoenix, USA), Larry Husten (CVCTCardioBrief, USA), Waheed Jamal (Boehringer Ingelheim, GER), Mehmood Khan (Life Biosciences, USA), Maciej Kostrubiec (EMA, POL), Stephen Kritchevsky (Winston-Salem, USA), Steven Nissen (Cleveland, USA), Donna Ryan (Baton Rouge, USA), Ellis Unger (FDA, USA), Janet Wittes (Washington, USA), Lisa Yanoff (FDA, USA)

HOW ARE PAYERS PREPARED TO VALUE CLINICAL EVIDENCE IN CARDIOVASCULAR MEDICINE?

Moderators: Biykem Bozkurt (Houston, USA) & Martin Cowie (Imperial College London, GBR)

Sunday, December 6th

18:00 – 20:00 Central European Time (CET)



Evidence-Based vs Value Based Medicine. Statistical vs Clinical vs Societal Meaningfulness Of Trial Results

Javed Butler (Jackson, USA)

Multi Stakeholders' Viewpoints

- **Health Economist Viewpoint**

Andrew Briggs (LSHTM, GBR)

- **Industry Viewpoint**

Maria Kubin (Bayer, GER)

- **HTA Viewpoint**

Adrian Jonas (NICE, London, GBR)

- **Clinical Viewpoint**

Amanda Adler (Oxford, GBR)

- **Patient Viewpoint**

Bray Patrick-Lake (Durham, USA)

The LIVE Forum **Multi-Stakeholder Moderated Debate** **HOW TRIALISTS ARE PREPARED TO LISTEN TO PAYERS NEEDS?**

Moderators: Biykem Bozkurt (Houston, USA) & Martin Cowie (Imperial College London, GBR)

Panelists: Amanda Adler (Oxford, GBR), Agim Beshiri (Abbott Dx, USA), Andrew Briggs (LSHTM, GBR), Javed Butler (Jackson, USA), Andrew Farb (FDA, USA), Charu Gandotra (FDA, USA), Adrian Jonas (NICE, London, GBR), Jennifer Jones (Abbott Vascular, USA), Harlan Krumholz (New Haven, USA), Maria Kubin (Bayer, GER), Roxana Mehran (New York, USA), Pieter Muntendam (G3Pharmaceuticals, USA), Bray Patrick-Lake (Durham, USA), Riccardo Perfetti (Applied therapeutics, USA), Krishna Prasad (MHRA, GBR), Dan Schaber (Medtronic, USA), Kenneth Stein (Boston Scientific, USA), Kartik Sundareswaran (Abbott, USA), Andre Ziegler (Roche Dx, CHE) Bram Zuckerman (FDA, USA)

Day 5 - Monday, December 7th, 2020

iCVCT 7

SHOCK AND STEMI TRIALS - HEMODYNAMIC SUPPORT IN SHOCK

Moderators: Navin Kapur (Boston, USA) & Sunil Rao (Durham, USA)

Monday, December 7th

13:30 – 15:30 Central European Time (CET)



Which device for whom? IABP, ECMO, Impella

Sripal Bangalore (New York, USA)

Trial Design Challenges in Shock

Holger Thiele (Leipzig, GER)

Endpoints in Shock

Sunil Rao (Durham, USA)

Adjudication challenges

Donald Cutlip (Boston, USA)

Regulatory Challenges for Device Approval

John Sapirstein (FDA, USA)

iCVCT

The LIVE Forum

Moderated Multi-Stake Holders debate

SHOCK AND STEMI TRIALS - HEMODYNAMIC SUPPORT IN SHOCK

Moderators: Navin Kapur (Boston, USA) & Sunil Rao (Durham, USA)

Panelists: Fernando Aguel (FDA, USA), Sripal Bangalore (New York, USA), Donald Cutlip (Boston, USA), Michael Gibson (Boston, USA), Timothy Henry (Los Angeles, USA), Dharam Kumbhani (Dallas, USA), Roxana Mehran (New York, USA), John Sapirstein (FDA, USA), Holger Thiele (Leipzig, GER), Pascal Vranckx (Hasselt, BEL)

iCVCT 8

STEMI TRIALS

Moderators: Timothy Henry (Los Angeles, USA) & Shami Mahmud (La Jolla, USA)

Monday, December 7th

16:00 – 18:00 Central European Time (CET)



Perspectives on Infarct Size as a Surrogate in STEMI trials

Navin K. Kapur (Boston, USA)

Devices in STEMI trials

Michael Gibson (Boston, USA)

iCVCT

The LIVE Forum

Moderated Multi-Stake Holders debate

STEMI trials

Moderators: Timothy Henry (Los Angeles, USA) & Shami Mahmud (La Jolla, USA)

Panelists: Fernando Aguel (FDA, USA), Sripal Bangalore (New York, USA), Donald Cutlip (Boston, USA), Michael Gibson (Boston, USA), Navin Kapur (Boston, USA), Dharam Kumbhani (Dallas, USA), Adrian Magee (FDA, USA), Roxana Mehran (New York, USA), Holger Thiele (Leipzig, GER), Sunil Rao (Durham, USA), Pascal Vranckx (Hasselt, BEL)

Day 5 - Monday, December 7th, 2020

iCVCT 9

TAVR TRIALS. REMAINING QUESTIONS, CHALLENGES, CONTROVERSIES IN APPROVAL PATHWAYS

Moderators: Michael Mack (Plano, USA) & Stephan Windecker (Bern, CHE)

Monday, December 7th

18:30 – 20:30 Central European Time (CET)



TAVR for Bicuspid Aortic Stenosis:

What Is Known and What Is Not

Michael Mack (Plano, USA)

TAVR for Aortic Regurgitation: Clinical Device Evaluation Considerations

Vinod Thourani (Atlanta, USA)

Heart Valve Collaboratory

Michael Mack (Plano, USA)

Valve Durability

Stephan Windecker (Bern, CHE)

Valve Pharmacology

Patrick O'Gara (Boston, USA)

Valve v. Valve Studies

Roxana Mehran (New York, USA)

Peri and Post Neuroprotection

Howard Herrmann (Philadelphia, USA)

Industry Viewpoints

Jeffrey Popma (Medtronic, USA)

Regulatory Considerations for New Valves and Adjunctive Devices

Jennifer Bastjanic (FDA, USA)

iCVCT

The LIVE Forum

Moderated Multi-Stake Holders debate

REMAINING QUESTIONS, CHALLENGES, CONTROVERSIES IN APPROVAL PATHWAYS IN TAVR TRIALS

Moderators: Michael Mack (Plano, USA) & Stephan Windecker (Bern, CHE)

Panelists: Jennifer Bastjanic (FDA, USA), Cathy Chen (Daiichi Sankyo, USA), George Dangas (New York, USA), Howard Herrmann (Philadelphia, USA), Hasan Jilaihawi (New York, USA), Roxana Mehran (New York, USA), Patrick O'Gara (Boston, USA), Jeffrey Popma (Medtronic, USA), Vinod Thourani (Atlanta, USA), Bernard Vasseur (FDA, USA)

www.globalcvctforum.com

Day 5 - Monday, December 7th, 2020

THE FUTURE OF HFrEF TRIALS

Moderators: John Cleland (Glasgow, GBR) & Milton Packer (Dallas, USA)

Monday, December 7th

13:30 - 15:50 Central European Time (CET)



And now, what is next? How will it be possible to launch new trials in HFrEF?

Javed Butler (Jackson, USA)

Shall we need implementation strategy trials? Precision? Sequencing? All «positive» drugs started at once?

Milton Packer (Dallas, USA)

Opportunities for fixed dose combination therapies?

Bertram Pitt (Ann Arbor, USA)

The promise of Novel miRNA antisense therapy in patients with heart failure

Thomas Thum (Cardior Pharmaceuticals, GER)

What else? What is in the drug pipelines for heart failure

John Cleland (Glasgow, GBR)

Industry viewpoint

Thomas Andersson (AstraZeneca, SWE), Martina Brueckmann (Boehringer Ingelheim, GER), Richard Nkulikiyinka (Bayer, GER), Benoit Tyl (Servier, FRA), Salim Shah (Sarfez, USA), Mahesh Patel (MSD, USA)

The LIVE Forum

Multi-Stakeholder Moderated Debate

THE FUTURE OF HFrEF TRIALS

Moderators: John Cleland (Glasgow, GBR) & Milton Packer (Dallas, USA)

Panelists: William Abraham (Columbus, USA), Thomas Andersson (AstraZeneca, SWE), Stefan Anker (Berlin, GER), Martina Brueckmann (Boehringer Ingelheim, GER), Daniel Burkoff (Cardiovascular Research Foundation, New York, NY, USA), Javed Butler (Jackson, USA), Preston Dunnmon (FDA, USA), Joao Ferreira (Nancy, FRA), Adrian Hernandez (Durham, USA), Nicole Ibrahim (FDA, USA), Christopher Kurtz (Amgen, USA), JoAnn Lindenfeld (Nashville, USA), Meir Shinnar (FDA, USA), Richard Nkulikiyinka (Bayer, GER), Mahesh Patel (MSD, USA), Bertram Pitt (Ann Arbor, USA), Stuart Pocock (London, GBR), Piotr Ponikowski (Wroclaw, POL), Michele Senni (Bergamo, ITA), Salim Shah (Sarfez, USA), Kenneth Stein (Boston Scientific, USA), Thomas Thum (Cardior Pharmaceuticals, GER), Benoit Tyl (Servier, FRA), Harriette Van Spall (Hamilton, CAN), Subodh Verma (Toronto, CAN), Faiez Zannad (Nancy, FRA), Bram D. Zuckerman (FDA, USA)

EPILOGUE

Milton Packer (Dallas, USA)

www.globalcvctforum.com

Day 5 - Monday, December 7th, 2020

IRON THERAPY IN HEART FAILURE FROM TRIAL EVIDENCE TO IMPLEMENTATION

Moderators: Inder Anand (San Diego, USA) & Ewa Jankowska (Wroclow, POL)

Monday, December 7th

16:00 – 18:00 Central European Time (CET)



Iron Deficiency In Stable Heart Failure The Evidence So Far

Inder Anand (San Diego, USA)

Lessons From Acute Heart Failure Trials So Far

Robert Mentz (Durham, USA)

Ferric Carboxymaltose For Iron Deficiency In Acute Heart Failure. The AFFIRM-HF Hard Outcomes Trial - Main Results

Piotr Ponikowski (Wroclow, POL)

What Patients Are Eligible Across The Heart Failure Continuum?

Stefan Anker (Berlin, GER)

Regulatory viewpoint

Charu Gandotra (FDA, USA)

Industry Viewpoint

Klaus Jensen (Vifor Pharma, CHE)

Patient Viewpoint

Cynthia Chauhan (Wichita, USA)

The LIVE Forum

Multi-stakeholder Moderated Debate

IRON THERAPY IN HEART FAILURE FROM TRIAL EVIDENCE TO IMPLEMENTATION

Moderators: Inder Anand (San Diego, USA) & Ewa Jankowska (Wroclow, POL)

Panelists: William Abraham (Columbus, USA), Thomas Andersson (AstraZeneca, SWE), Stefan Anker (Berlin, GER), Javed Butler (Jackson, USA), Cynthia Chauhan (Wichita, USA), John Cleland (Glasgow, GBR), Joao Ferreira (Nancy, FRA), Gerasimos Filippatos (Athens, GRE), Charu Gandotra (FDA, USA), Adrian Hernandez (Durham, USA), Klaus Jensen (Vifor Pharma, CHE), JoAnn Lindenfeld (Nashville, USA), Robert Mentz (Durham, USA), Peter Mol (EMA, NED), Milton Packer (Dallas, USA), Mahesh Patel (MSD, USA), Bertram Pitt (Ann Arbor, USA), Stuart Pocock (London, GBR), Piotr Ponikowski (Wroclow, POL), Michele Senni (Bergamo, ITA), Kenneth Stein (Boston Scientific, USA), Benoit Tyl (Servier, FRA), Faiez Zannad (Nancy, FRA)

PATHWAYS TO ENHANCE BIOMARKER VALUE – IMAGINING INNOVATION

Moderators: Kirkwood Adams (Chapel Hill, USA) & Alexandre Mebazaa (Paris, FRA)

Monday December 7th

18:30 – 20:30 Central European Time (CET)



Innovations In Biomarker Research

• Progress In Bio-Analytical Methods

Anissa Lamarque (Olink, FRA), Andre Ziegler (Roche Dx, CHE)

• Innovative Proteomics In Cardiovascular Disease

Lars Wallentin (Stockholm, SWE)

Biomarkers For Understanding Molecular Mechanisms Of Diseases

• Leveraging Biomarkers And Omics To Elucidate Mechanisms Of Novel HFrEF Therapy

- HOMAGE

Faiez Zannad (Nancy, FRA)

• Biomarkers As Biotargets In Sepsis And Cardiogenic Shock

Alexandre Mebazaa (Paris, FRA)

Day 5 - Monday, December 7th, 2020

The LIVE Forum
Multi-stakeholder Moderated Debate
PATHWAYS TO ENHANCE BIOMARKER VALUE – IMAGINING INNOVATION
Moderators: Kirkwood Adams (Chapel Hill, USA) & Alexandre Mebazaa (Paris, FRA)

Panelists: Agim Beshiri (Abbott Dx, USA), Karine Bourgeois (4TEEN4 Pharmaceuticals GmbH, GER), Lawrence Fine (NHLBI, USA), Ziad Hijazi (Uppsala, SWE), Jack Lawrence (Janssen, USA), Anissa Lamarque (Olink, FRA), Sandra Sanders-van Wijk (Maastricht, NED), Lars Wallentin (Stockholm, SWE), Faiez Zannad (Nancy, FRA), Andre Ziegler (Roche Dx, CHE)

www.globalcvctforum.com

CVCT young investigator grants (CVCT YIGs)

CVCT YIG was developed with the main goal of forming a new generation of investigators in cardiovascular field.

Young fellows can apply for a Young Investigator grant to attend the annual CVCT forum and most of our young fellow attendees would testify that attending CVCT is a real turning point in their career.

The intimate nature of CVCT provided them with the rare opportunity of having one-on-one conversations with many senior principal investigators/mentors with a long-record of clinical trials, that they would have never had access to otherwise, in big meetings nor at their educational institutions.

Our scientific committee learns about candidates in the following ways:

- Grant applications submitted via the CVCT website - www.globalcvctforum.com
- Nomination by CVCT faculty members

CVCT Meetings are supported by unrestricted educational grants with no allocation for speakers fees. In recognition of the valued contribution of faculty members and with a view to attracting young investigators to the field of cardiovascular clinical trial science, CVCT invites faculty members to recommend one fellow who could be invited to attend the CVCT Forum.

The full list of grantees is available on our website: www.globalcvctforum.com

AHA FIT & CVCT 2020 Partnership



Jointly endorsed by the AHA FIT Program and The Global CardioVascular Clinical Trialists Forum (CVCT), the aim of this program is to assist young investigators in forming their future as CardioVascular Clinical Trialists and give a substantial boost to their career; a vision that both the AHA FIT & CVCT Young Trialist programs have in common.

www.globalcvctforum.com

CVCT-PHARMA internship initiative

The CVCT-PHARMA internship initiative offers young specialists and residents within cardiovascular specialties, to work as part of PHARMA study teams in all phases of clinical development within the cardiovascular, renal and metabolic areas. The focus will be on CV outcome trials, but there may also be opportunities to engage in e.g. mechanistic studies. This training includes all activities related to late phase studies, e.g. protocol development, preparation of charters for study committees and the statistical analysis plan, collaboration with the endpoint office and committee, CRF development, risk-based monitoring and safety surveillance. During study set-up, responding to regulatory and IRB questions may be included. While the study is ongoing, the young faculty will be embedded within the research team and involved in everyday operational activities. Depending on trial timing, the individual may have a role in data interpretation and dissemination as well.

CVCT future trialist fellowship initiative

The CVCT Future trialists fellowship initiative enables young fellows and mid career faculty to train, joining major principal investigators and mentor trialists as a «Steering committee Mentee», joining the steering committee of an ongoing major clinical trial, as a full member, learning about the conduct of the trial, and data collection, analyses and interpretation, and co-authoring with the trial leadership secondary trial manuscripts.

www.globalcvctforum.com

CVCT library and CVCT publications

We offer a complete record of previous CVCT Forum presentations, including the webcast programs for 2011 and 2012, which are freely available on our website: www.globalcvctforum.com

The CVCT Library includes webcasts of selected sessions and slide sets from most of the presentations and the latest CVCT publications. In addition we are pleased to welcome this year's young writer team. The dedicated CVCT writing group produces manuscripts resulting from high-level scientific discussions at the CVCT Forum, working with key faculty and leadership from the sessions. The writing group is led by Dr. Ferreira and Dr. Vaduganathan as they work with junior faculty and fellows.

CVCT PUBLICATIONS REFERENCE LIST

Visit www.globalcvctforum.com to read the articles in full

2018

Antihyperglycemic Therapies to Treat Patients With Heart Failure and Diabetes Mellitus

Sharma A, Cooper LB, Fiuzat M, Mentz RJ, Ferreira JP, Butler J, Fitchett D, Moses AC, O'Connor C, Zannad F. JACC Heart Fail. 2018 Oct;6(10):813-822.

Reassessing the Role of Surrogate End Points in Drug Development for Heart Failure

Greene SJ, Mentz RJ, Fiuzat M, Butler J, Solomon SD, Ambrosy AP, Mehta C, Teerlink JR, Zannad F, O'Connor CM. Circulation. 2018 Sep 4;138(10):1039-1053.

The role of angiotensin receptor-neprilysin inhibitors in cardiovascular disease-existing evidence, knowledge gaps, and future directions

Ambrosy AP, Mentz RJ, Fiuzat M, Cleland JGF, Greene SJ, O'Connor CM, Teerlink JR, Zannad F, Solomon SD. Eur J Heart Fail. 2018 Jun;20(6):963-972.

Evolution of natriuretic peptide biomarkers in heart failure: Implications for clinical care and clinical trials

Vodovar N, Mebazaa A, Januzzi JL Jr, Murtagh G, Stough WG, Adams KF Jr, Zannad F. Int J Cardiol. 2018 Mar 1;254:215-221

2017

ERole of Payers in the Development of Cardiovascular Therapeutics: Misalignment Between Approval and Reimbursement

Zannad F, Alonso Garcia MLA, Borer JS, Stough WG, Clutton-Brock T, Rosenberg Y, Packer M., J Am Coll Cardiol. 2017 Dec 5;70(22):2822-2830.

Tailoring mineralocorticoid receptor antagonist therapy in heart failure patients: are we moving towards a personalized approach?

Ferreira JP, Mentz RJ, Pizard A, Pitt B, Zannad F. Eur J Heart Fail. 2017 Aug;19(8):974-986.

Declining Risk of Sudden Death in Heart Failure

Shen L, Jhund PS, Petrie MC, Claggett BL, Barlera S, Cleland JGF, Dargie HJ, Granger CB, Kjekshus J, Køber L, Latini R, Maggioni AP, Packer M, Pitt B, Solomon SD, Swedberg K, Tavazzi L, Wikstrand J, Zannad F, Zile MR, McMurray JJV. N Engl J Med. 2017 Jul 6;377(1):41-51

The burden of proof: The current state of atrial fibrillation prevention and treatment trials

Zakeri R, Van Wagoner DR, Calkins H, Wong T, Ross HM, Heist EK, Meyer TE, Kowey PR, Mentz RJ, Cleland JG, Pitt B, Zannad F, Linde C. Heart Rhythm. 2017 May;14(5):763-782.

CVCT library and CVCT publications

Evolution of natriuretic peptide biomarkers in heart failure: implications for clinical care and clinical trials

Vodovar N, Mebazaa A, Januzzi JL, Murtagh G, Stough WG, Adams KF, Zannad F. *Int J Cardiol* (2017); in press.

Streamlining cardiovascular clinical trials to improve efficiency and generalisability

Zannad F, Pfeffer MA, Bhatt DL, Bonds DE, Borer JS, Calvo-Rojas G, Fiore L, Lund LH, Madigan D, Maggioni AP, Meyers CM, Rosenberg Y, Simon T, Stough WG, Zalewski A, Zariffa N, Temple R. *Heart* 2017;103(15):1156-1162.

Cardiovascular Outcome Trials in Patients with Advanced Kidney Disease: Time for Action

Zannad F, Rossignol P. *Circulation* 2017;135(19):1769-1771.

Role of payers in the development of cardiovascular therapeutics. Misalignment between approval and reimbursement.

Zannad F, Alonso Garcia M, Borer JS, Stough WG, Clutton-Brock T, Rosenberg Y, Packer M. *J Am Coll Cardiol* 2017;doi: 10.1016/j.jacc.2017.10.027.

2016

New approaches to hyperkalemia in patients with indications for renin angiotensin aldosterone inhibitors: Considerations for trial design and regulatory approval

Zannad F, Rossignol P, Stough WG, Epstein M, Alonso Garcia Mde L, Bakris GL, Butler J, Kosiborod M, Berman L, Mebazaa A, Rasmussen HS, Ruilope LM, Stockbridge N, Thompson A, Wittes J, Pitt B. *Int J Cardiol* (2016) 216:46-51.

Assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment vs. risk aversion

Zannad F, Stough WG, Lipicky RJ, Tamargo J, Bakris GL, Borer JS, Alonso Garcia Mde L, Hadjadj S, Koenig W, Kupfer S, McCullough PA, Mosenzon O, Pocock S, Scheen AJ, Sourij H, Van der Schueren B, Stahre C, White WB, Calvo G. *Eur Heart J Cardiovasc Pharmacother* (2016) 2(3):200-205.

2015

Design considerations for clinical trials of autonomic modulation therapies targeting hypertension and heart failure

Zannad F, Stough WG, Mahfoud F, Bakris GL, Kjeldsen SE, Kieval RS, Haller H, Yared N, De Ferrari GM, Pina IL, Stein K, Azizi M. *Hypertension* (2015) 65(1):5-15.

Agents with vasodilator properties in acute heart failure: how to design successful trials

Mebazaa A, Longrois D, Metra M, Mueller C, Richards AM, Roessig L, Seronde MF, Sato N, Stockbridge N, Gattis Stough W, Alonso A, Cody R, Cook Bruns N, Gheorghiade M, Holzmeister J, Laribi S, Zannad F. *European Journal of Heart Failure* (2015) 17, 652–664 doi:10.1002/ejhf.294. Review.

Cardiac resynchronization therapy in heart failure patients with less severe left ventricular dysfunction

Hai OY, Mentz RJ, Zannad F, Gasparini M, De Ferrari GM, Daubert JC, Holzmeister J, Lam CS, Pochet T, Vincent A, Linde C. *Eur J Heart Fail.* 2015 Feb;17(2):135-43. doi: 10.1002/ejhf.208. Epub 2014 Dec 3.
Patient selection in heart failure with preserved ejection fraction clinical trials
Kelly JP, Mentz RJ, Mebazaa A, Voors AA, Butler J, Roessig L, Fiuzat M, Zannad F, Pitt B, O'Connor CM, Lam CS. *J Am Coll Cardiol.* 2015 Apr 28;65(16):1668-82. doi: 10.1016/j.jacc.2015.03.043.

CVCT library and CVCT publications

Atherosclerosis: recent trials, new targets and future directions

Ladeiras-Lopes R, Agewall S, Tawakol A, Staels B, Stein E, Mentz RJ, Leite-Moreira A, Zannad F, Koenig W. *Int J Cardiol.* 2015 Aug 1;192:72-81. doi: 10.1016/j.ijcard.2015.05.013. Epub 2015 May 8. Review.

2014

Heart rate: a prognostic factor and therapeutic target in chronic heart failure. The distinct roles of drugs with heart rate-lowering properties.

Dobre D, Borer JS, Fox K, Swedberg K, Adams KF, Cleland JG, Cohen-Solal A, Gheorghiade M, Gueyffier F, O'Connor CM, Fiuzat M, Patak A, Piña IL, Rosano G, Sabbah HN, Tavazzi L, Zannad F. *Eur J Heart Fail.* 2014 Jan;16(1):76-85.

Decongestion in acute heart failure

Mentz RJ, Kjeldsen K, Rossi GP, Voors AA, Cleland JG, Anker SD, Gheorghiade M, Fiuzat M, Rossignol P, Zannad F, Pitt B, O'Connor C, Felker GM. *Eur J Heart Fail.* 2014 May;16(5):471-82.

Current challenges for clinical trials of cardiovascular medical devices

Zannad F, Stough WG, Piña IL, Mehran R, Abraham WT, Anker SD, De Ferrari GM, Farb A, Geller NL, Kieval RS, Linde C, Redberg RF, Stein K, Vincent A, Woehrle H, Pocock SJ. *Int J Cardiol.* 2014 Jul 15;175(1):30-7. <http://dx.doi.org/10.1016/j.ijcard.2014.05.021>

Trials of implantable monitoring devices in heart failure: which design is optimal?

Nat Rev Cardiol. 2014 Oct;11(10):576-85. Abraham WT, Stough WG, Piña IL, Linde C, Borer JS, De Ferrari GM, Mehran R, Stein KM, Vincent A, Yadav JS, Anker SD, Zannad F. *Nature Reviews Cardiology* 2014 doi:10.1038/nrcardio.2014.114

Charting a roadmap for heart failure biomarker studies

Ahmad T, Fiuzat M, Pencina MJ, Geller NL, Zannad F, Cleland JG, Snider JV, Blankenberg S, Adams KF, Redberg RF, Kim JB, Mascette A, Mentz RJ, O'Connor CM, Felker GM, Januzzi JL. *JACC Heart Fail.* 2014 Oct;2(5):477-488.

Design considerations for clinical trials of autonomic modulation therapies targeting hypertension and heart failure

Zannad F, Stough WG, Mahfoud F, Bakris GL, Kjeldsen SE, Kieval RS, Haller H, Yared N, De Ferrari GM, Piña IL, Stein K, Azizi M. *Hypertension.* 2014 Oct 27.

Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction

Mentz RJ, Kelly JP, von Lueder TG, Voors AA, Lam CS, Cowie MR, Kjeldsen K, Jankowska EA, Atar D, Butler J, Fiuzat M, Zannad F, Pitt B, O'Connor CM. *J Am Coll Cardiol.* 2014 Dec 2;64(21):2281-93. doi: 10.1016/j.jacc.2014.08.036. Epub 2014 Nov 24. Review.

2013

Antithrombotic outcome trials in acute coronary syndromes: seeking the optimal balance between safety and efficacy

Verheugt FW, Clemmensen P, Mehran R, Agewall S, Pocock SJ, Goldstein S, Torp-Pedersen C, Simoons-Sel A, Borer JS, Khder YM, Burton P, Deliargyris E, McMurray JJ, Berkowitz SD, Stough WG, Zannad F. *Eur Heart J.* 2013 Jun;34(22):1621-9.

CVCT library and CVCT publications

Biomarker-guided therapies in heart failure: a forum for unified strategies

Fiuzat M, O'Connor CM, Gueyffier F, Mascette AM, Geller NL, Mebazaa A, Voors AA, Adams KF, Piña IL, Neyses L, Muntendam P, Felker GM, Pitt B, Zannad F, Bristow MR. J Card Fail. 2013 Aug;19(8):592-9.

The past, present and future of renin-angiotensin aldosterone system inhibition

Mentz RJ, Bakris GL, Waeber B, McMurray JJ, Gheorghiade M, Ruilope LM, Maggioni AP, Swedberg K, Piña IL, Fiuzat M, O'Connor CM, Zannad F, Pitt B. Int J Cardiol. 2013 Sep 1;167(5):1677-87.

Is thrombosis a contributor to heart failure pathophysiology? Possible mechanisms, therapeutic opportunities, and clinical investigation challenges

Zannad F, Stough WG, Regnault V, Gheorghiade M, Deliargyris E, Gibson CM, Agewall S, Berkowitz SD, Burton P, Calvo G, Goldstein S, Verheugt FW, Koglin J, O'Connor CM. International Journal of Cardiology 167 (2013) 1772-1782 Int J Cardiol. 2013 Sep 1;167(5):1772-82.

Learning from recent trials and shaping the future of acute heart failure trials

Mentz RJ, Felker GM, Ahmad T, Peacock WF, Pitt B, Fiuzat M, Maggioni AP, Gheorghiade M, Ando Y, Pocock SJ, Zannad F, O'Connor CM. Am Heart J. 2013 Oct;166(4):629-35.

Publication of trials funded by the National Heart, Lung, and Blood Institute

Gordon D, Taddei-Peters W, Mascette A, Antman M, Kaufmann PG, Lauer MS. The New England Journal of Medicine 2012, November 14, 369:20.

2012

Targeting the aldosterone pathway in cardiovascular disease

Gustafsson F, Azizi M, Bauersachs J, Jaisser F, Rossignol P. Fundam Clin Pharmacol. 2012 Feb;26(1):135-45.

When to stop a clinical trial early for benefit: lessons learned and future approaches 2012

Zannad F, Gattis Stough W, McMurray JJ, Remme WJ, Pitt B, Borer JS, Geller NL, Pocock SJ. Circ Heart Fail. 2012 Mar 1;5(2):294-302.

Implications of geographical variation on clinical outcomes of cardiovascular trials

Mentz RJ, Kaski JC, Dan GA, Goldstein S, Stockbridge N, Alonso-Garcia A, Ruilope LM, Martinez FA, Zannad F, Pitt B, Fiuzat M, O'Connor CM. Am Heart J. 2012 Sep;164(3):303-12.

Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice

Zannad F, Gattis Stough W, Rossignol P, Bauersachs J, McMurray JJ, Swedberg K, Struthers AD, Voors AA, Ruilope LM, Bakris GL, O'Connor CM, Gheorghiade M, Mentz RJ, Cohen-Solal A, Maggioni AP, Beygui F, Filippatos GS, Massy ZA, Pathak A, Piña IL, Sabbah HN, Sica DA, Tavazzi L, Pitt B. Eur Heart J. 2012 Nov;33(22):2782-95.

2010

Maximizing scientific knowledge from randomized clinical trials

Gustafsson F, Atar D, Pitt B, Zannad F, Pfeffer MA; participants in 10th Cardiovascular Clinical Trialists Workshop. Am Heart J. 2010 Jun;159(6):937-43.

CVCT library and CVCT publications

2009

Unconventional end points in cardiovascular clinical trials: should we be moving away from morbidity and mortality?

Journal of Cardiac Failure 2009;15:199-205.

Cohn JI, Cleland JG, Lubsen J, Borer JS, Steg PG, Perelman M, Zannad F. J Card Fail. 2009 Apr;15(3):199-205.

2008

Heart failure as an endpoint in heart failure and non-heart failure cardiovascular clinical trials: the need for a consensus definition

Zannad F, Stough WG, Pitt B, Cleland JG, Adams KF, Geller NL, Torp-Pedersen C, Kirwan BA, Follath F.

Eur Heart J. 2008 Feb;29(3):413-21

When should data and safety monitoring committees share interim results in cardiovascular trials?

Borer JS, Gordon DJ, Geller NL. JAMA. 2008 Apr 9;299(14):1710-2.

Similarities and differences in design considerations for cell therapy and pharmacologic cardiovascular clinical trials

Lewis RM, Gordon DJ, Poole-Wilson PA, Borer JS, Zannad F. Cardiology. 2008;110(2):73-80.

2007

Cardiovascular safety of drugs not intended for cardiovascular use: need for a new conceptual basis for assessment and approval

European Heart Journal 2007;28:1904-1909. Borer JS1, Pouleur H, Abadie E, Follath F, Wittes J, Pfeffer MA, Pitt B, Zannad F.

Globalization of cardiovascular clinical research: the balance between meeting medical needs and maintaining scientific standards

American Heart Journal 2007;154:232-8 Stough WG1, Zannad F, Pitt B, Goldstein S. Am Heart J. 2007

www.globalcvctforum.com

Partner societies



Nancy Inserm 1433 Clinical Plurithematic Investigation Centre (CIC-P), headed by Pr Faiez Zannad, is supported by the National Institution for Health Care and Medical Research (Inserm), Nancy University Hospital, and the Université de Lorraine.

With its staff specifically dedicated to clinical research, it acts as an interface between basic research and completed medical research, and its purpose is to produce new scientific and medical knowledge in compliance with ethical and legal standards. The CIC objectives are:

- To provide logistical and technical support for the design and implementation of research projects.
- To develop clinical research especially in cardiovascular diseases, aging and metabolism, within the community of university hospitals and research laboratories, and in particular within Inserm, as well as with general hospitals and health care facilities and private practice investigators.
- To train physicians, pharmacists and paramedics in clinical research, the use of good clinical practices and quality control.

The CIC provides support throughout each entire project, from the preparatory stage to termination and follow-up.

www.chu-nancy.fr



The **American Heart Association** has long supported scientific research in our fight against heart disease and stroke. And we're making a difference. The research we've funded through the generosity of our donors is helping more and more people survive heart disease and stroke. Our core research programs have launched or furthered the work of many of this country's brightest researchers. And we've added research awards that foster team science and accelerate discovery.

www.heart.org



The **European Medicines Agency (EMA)** is a decentralized agency of the European Union, located in London. The Agency is responsible for the scientific evaluation of medicines developed by pharmaceutical companies for use in the European Union. It began operating in 1995.

www.ema.europa.eu



The **Food and Drug Administration (FDA)** is responsible for protecting the public health by ensuring the safety, efficacy, and security of human and veterinary drugs, biological products, and medical devices; and by ensuring the safety of our nation's food supply, cosmetics, and products that emit radiation.

www.fda.gov



The **Investigation Network Initiative (INI)** – Cardiovascular and Renal Clinical Trialists (CRCT), coordinated by Pr Patrick Rossignol (Nancy,

France) has been approved by the "F-CRIN" (French Clinical Research Infrastructure Network). It has established a national multidisciplinary network of research excellence comprised of the French leaders in the cardiorenal field (nephrology, cardiology, intensivists, internists, trialists, epidemiologists, methodologists, basic researchers), an Academic Research Organisation, disease management programs in Chronic Kidney disease (CKD) and heart failure, the French Biomedicine agency, and University of Lorraine Foundation. It aims at designing and realizing research programs both nationally and internationally, to improve cardiovascular and renal outcomes in CKD patients.

www.inicrt.org



The **National Heart, Lung, and Blood Institute (NHLBI)** provides global leadership for a research, training, and education program to promote the prevention and treatment of heart, lung, and blood diseases and enhance the health of all individuals so that they can live longer and more fulfilling lives.

www.nhlbi.nih.gov



Women as One will serve as a unifying thread across the many important organizations and individuals working to improve the recruitment, retention and treatment of women in medical specialties where they are highly underrepresented.

www.womenasone.org

Partnership: Roxana Mehran



William Abraham
(Columbus, USA)




Kirkwood Adams
(Chapel Hill, USA)



Amanda Adler
(Oxford, GBR)



Rajiv Agarwal
(Indianapolis, USA)



Inder Anand
(San Diego, USA)



Dominick Angiolillo
(Jacksonville, USA)




Stefan Anker
(Berlin, GER)



Charalambos Antoniades
(Oxford, GBR)



Paul W. Armstrong
(Alberta, CAN)



Suzanne Arnold
(Kansas City, USA)




Michel Azizi
(Paris, FRA)




George Bakris
(Chicago, USA)



Sripal Bangalore
(New York, USA)



Nir Barzilai
(New York, USA)



Jeffrey Borer
(New York, USA)



Barry Borlaug
(Minneapolis, USA)



Deepak Bhatt
(Boston, USA)




Biykem Bozkurt
(Houston, USA)



Eugene Braunwald
(Boston, USA)



Javed Butler
(Jackson, USA)




Robert Califf
(Verily, USA)




Davide Cao
(New York, USA)




Davide Capodanno
(Catania, ITA)



Peter Carson
(Chapel Hill, USA)



Barbara Casadei
(London, GBR)



Michael Charlton
(Chicago, USA)




John Cleland
(Glasgow, GBR)



Jan H. Cornel
(Nijmegen, NED)



Donald Cutlip
(Boston, USA)



Thibaud Damy
(Paris, FRA)



George Dangas
(New York, USA)



Christopher deFilippi
(Washington, USA)



David DeMets
(Madison, USA)




Thomas Deering
(Atlanta, USA)



Susan Ellenberg
(Philadelphia, USA)



Murray Epstein
(Miami, USA)



Michael Felker
(Durham, USA)



Joao Ferreira
(Nancy, FRA)



Gemma Figtree
(Sydney, AUS)



Gerasimos Filippatos
(Athens, GRE)



Bernard Gersh
(Rochester, USA)



Michael Gibson
(Boston, USA)



Robert Giugliano
(Boston, USA)



Chris Granger
(Durham, USA)



John Gregson
(London, GBR)



Barry Greenberg
(La Jolla, USA)



Mayra Guerrero
(Rochester, USA)




Rebecca Hahn
(New York, USA)



Stephen Harrison
(San Antonio, USA)



Hiddo Heerspink
(Groningen, NED)



Timothy Henry
(Los Angeles, USA)



Howard Herrmann
(Philadelphia, USA)



Adrian Hernandez
(Durham, USA)



Ziad Hijazi
(Uppsala, SWE)



Joseph A Hill
(Dallas, USA)



Gerhard Hindricks
(Leipzig, GER)



Carolyn Ho
(Boston, USA)



Elaine Hylek
(Boston, USA)




Tiny Jaarsma
(Linköping, SWE)



Dan Jacoby
(Yale, USA)




Stefan James
(Uppsala, SWE)



Ewa Jankowska
(Wrocław, POL)




Meg Jardine
(Sydney, AUS)




Hasan Jilaihawi
(New York, USA)

Faculty members 2020

Academia



Mehmood Khan
(Boston, USA)




David Kao
(Colorado, USA)



Navin Kapur
(Boston, USA)



Padma Kaul
(Edmonton, CAN)



Wolfgang Koenig
(Munich, GER)



Mikhail Kosiborod
(Missouri, USA)



Stephen Kritchevsky
(Winston-Salem, USA)



Harlan Krumholz
(New Haven, USA)



Dharam Kumbhani
(Dallas, USA)



Ulf Landmesser
(Berlin, GER)




Carolyn Lam
(Singapore, SIN)




Peter Libby
(Boston, USA)




Cecilia Linde
(Stockholm, SWE)




JoAnn Lindenfeld
(Nashville, USA)




**Teresa Lopez
Fernandez** (Madrid, ESP)




Michael Mack
(Plano, USA)




Andrea Maier
(Melbourne, AUS)




Shami Mahmud
(La Jolla, USA)



Douglas Mann
(Saint Louis, USA)



Daniel Mark
(Durham, USA)



Marty Maron
(Boston, USA)



Alexandre Mebazaa
(Paris, FRA)



Mandeep Mehra
(Boston, USA)



Roxana Mehran
(New York, USA)




Robert Mentz
(Durham, USA)



Erin Michos
(Baltimore, USA)



Sankar Navaneethan
(Houston, USA)




Steven Nissen
(Cleveland, USA)



Patrick O'Gara
(Boston, USA)



Iacopo Olivotto
(Florence, ITA)




Rebecca Ortega
(Durham, USA)



Milton Packer
(Dallas, USA)




Marc Pfeffer
(Boston, USA)



Jon Piccini
(Durham, USA)



Burkert Pieske
(Berlin, GER)



Ileana Piña
(Detroit, USA)



Bertram Pitt
(Ann Arbor, USA)




Stuart Pocock
(London, GBR)




Piotr Ponikowski
(Wroclaw, POL)




David Preiss
(Oxford, GBR)




Sunil Rao
(Durham, USA)



Kausik Ray
(London, GBR)



Vivek Reddy
(New York, USA)



Paul Ridker
(Boston, USA)




Julio Rosenstock
(Dallas, USA)



Peter Rossing
(Copenhagen, DEN)




Patrick Rossignol
(Nancy, FRA)



Andrea Russo
(Camden, USA)



Donna Ryan
(Baton Rouge, USA)



Sandra Sanders-van Wijk
(Maastricht, NED)



Arun Sanyal
(Richmond, USA)




Naveed Sattar
(Glasgow, GBR)



Michael Schmoeckel
(Hamburg, GER)



Benjamin Scirica
(Boston, USA)




Michele Senni
(Bergamo, ITA)



Sanjiv Shah
(Chicago, USA)




Abhinav Sharma
(Montreal, CAN)




Tabassome Simon
(Paris, FRA)



Scott Solomon
(Boston, USA)



John Spertus
(Kansas City, USA)



Lynne Stevenson
(Nashville, USA)



Jean-Claude Tardif
(Montreal, CAN)



John Teerlink
(San Francisco, USA)




Jeffrey Testani
(New Haven, USA)




Holger Thiele
(Leipzig, GER)




Jan Tijssen
(Nijmegen, NED)



Vinod Thourani
(Atlanta, USA)



Estefanía Toledo
(Madrid, ESP)



Mintu Turakhia
(Stanford, USA)



Katherine Tuttle
(Seattle, USA)



Muthiah Vaduganathan
(Boston, USA)




Harriette Van Spall
(Hamilton, CAN)



Subodh Verma
(Toronto, CAN)




Annabelle Volgman
(Chicago, USA)




Lars Wallentin
(Stockholm, SWE)




Christoph Wanner
(Wursburg, GER)



Mary Walsh
(Baltimore, USA)



David Wheeler
(London, GBR)



Stephan Windecker
(Bern, CHE)




Lijing Yan
(Kunshan, CHN)

Faculty members 2020 --- Academia




Faiez Zannad
(Nancy, FRA)

Faculty members 2020 --- Journal



Joseph Alpert (American J
Medicine, Tucson, USA)



Filippo Crea
(Eur Heart Journal, ITA)



Robert Golub
(JAMA, Washington, USA)




John Jarcho
(NEJM, Boston, USA)



Stuart Spencer
(The Lancet, London, GBR)

Faculty members 2020

Media



Martha Gulati
(Phoenix, USA)



Larry Husten
(CVCTCardioBrief, USA)

Faculty members 2020

Industry




Brooke Allocco
(Boston Scientific, USA)



Thomas Andersson
(AstraZeneca, SWE)



Jodi Akin
(Hawthorne Effect, USA)



Luke Bamber
(Bayer, GER)




Elliot Barnathan
(JnJ, USA)



Adriane Berg
(Kinexum, USA)



Agim Beshiri
(Abbott Dx, USA)



François Henri Boissel
(Novadiscovery, FRA)

Faculty members 2020

Industry



Antonieta Bomfim Wirtz
(Bayer, GER)




Karine Bourgeois
(4TEEN4 Pharmaceuticals GmbH, GER)



Martina Brueckmann
(Boehringer, GER)



Daniel Burkhoff
(Cardiovascular Research Foundation, New York, NY, USA)



Manu Chakravarthy
(Axcella, USA)



Cathy Chen
(Daiichi Sankyo, USA)



Erin Clayton
(Good Food Institute, USA)



Thomas Clozel
(Owkin, France)




Graziella Collu
(AstraZeneca, SWE)



Gad Cotter
(Momentum Research, USA)



Beth Davison
(Momentum Research, USA)



Michael Davidson
(Corvidia, USA)




Efthymios Deliargyris
(Cytosorbents, USA)



Howard Dittrich
(Cirius Pharmaceutical, USA)




Saliu Drilon
(Philips, USA)



Jay Edelberg
(BMS, USA)

Faculty members 2020

Industry




Irina Elyubaeva
(Servier, FRA)




Alexander Fleming
(Kinexum, USA)



Steven Gough
(Novonordisk, DEN)



Craig Granowitz
(Amarin, USA)




Abraham Gutman
(AG Mednet, USA)



Sibylle Hauske
(Boehringer, GER)




Narimon Honarpour
(Amgen, USA)



Kees Hovingh
(NovoNordisk, DEN)




Jianying Hu
(IBM, USA)



Thomas Idorn
(NovoNordisk, USA)



Waheed Jamal
(Boehringer, GER)



Klaus Jensen
(Vifor Pharma, CHE)



Jennifer Jones
(Abbott Vascular, USA)



Amer Joseph
(Bayer, GER)



Bronwyn Kingwell
(CSL, Melbourne, AUS)



Rob Kowal
(Medtronic, USA)

Faculty members 2020


Industry



Tamara Krcmar
(Servier, FRA)



Maria Kubin
(Bayer, GER)



Christopher Kurtz
(Amgen, USA)



Anissa Lamarque
(Olink, SWE)



Anna-Maria Langkilde
(Astrazeneca, SWE)



Jack Lawrence
(Janssen, USA)



Martin Lefkowitz
(Novartis, USA)



Fady Malik
(Cytokinetics, USA)



Laura Mauri
(Medtronic, USA)




Pieter Muntendam
(G3Pharmaceuticals, USA)




Manuela Negoita
(Medtronic, USA)




Richard Nkulikiyinka
(Bayer, GER)




Matias Nordaby
(Boehringer, GER)



Mahesh Patel
(MSD, USA)



Riccardo Perfetti
(Applied therapeutics, USA)



Jeffrey Popma
(Medtronic, USA)

Faculty members 2020

Industry




James Revkin
(Pfizer, USA)



Jeffrey Riesmeyer
(Lilly, USA)




Lothar Roessig
(Bayer, GER)



Jerome Rossert
(Astrazeneca, SWE)



Dan Schaber
(Medtronic, USA)



William Smith
(Alexion, USA)



Monica Shah
(IQVIA, USA)



Salim Shah
(Sarfez, USA)




Chuck Simonton,
(Abiomed, USA)



Bergur Stefansson
(AstraZeneca, SWE)



Kenneth Stein
(Boston Scientific, USA)



James Strait
(Merck, USA)



Kartik Sundareswaran
(Abbott, USA)



Thomas Thum
(Cardior Pharmaceuticals,
GER)



Tom Thuren
(Novartis, USA)




Benoit Tyl
(Servier, FRA)

Faculty members 2020


Industry



Martin Unverdorben
(Daiichi-Sankyo, USA)




Claire Varin
(Servier, FRA)



Ola Vedin
(Boehringer, GER)



Janet Wittes
(Washington, USA)



Hans Juergen Woerle
(Nestlé HealthScience,
CHE)



Fred Yang
(KBP Biosciences, USA)



Nadim Yared
(CVRx, USA)



Andre Ziegler
(Roche Dx, CHE)

Faculty members 2020

Regulatory



Fernando Aguel
(FDA, USA)




Angeles Alonso
(MHRA, GBR)



Frank Anania
(FDA, USA)



Ariel Ash-Shakoor
(FDA, USA)



Jennifer Bastijanec
(FDA, USA)



Nikolai Brun
(EMA, DEN)



Preston Dunnmon
(FDA, USA)




Kan Fang
(FDA, USA)




Andrew Farb
(FDA, USA)



Luigi Ferrucci
(NIH, USA)




Lawrence Fine
(NHLBI, USA)



Charu Gandotra
(FDA, USA)




Lydia Glaw
(FDA, USA)



Nicole Ibrahim
(FDA, USA)



Robert Kazmierski
(FDA, USA)



Maciej Kostrubiec
(EMA, POL)

Faculty members 2020

Regulatory




Michael Lauer
(NIH, USA)



Adrian Magee
(FDA, USA)



Peter Mol
(EMA, NED)




Mauro Moscucci
(FDA, USA)



Elektra Papadopoulos
(FDA, USA)



Bakul Patel
(FDA, USA)



Jessica Paulsen
(FDA, USA)




Gail Pearson
(NHLBI, USA)




Krishna Prasad
(EMA, GBR)



Ivor Pritchard
(Office for Human
Research Protections,
USA)



Jaime Raben
(FDA, USA)



Giuseppe Rosano
(EMA, GBR)




Yves Rosenberg
(NHLBI, USA)



John Sapirstein
(FDA, USA)




Fred Senatore
(FDA, USA)



John Sharretts
(FDA, USA)



Meir Shinnar
(FDA, USA)



Norman Stockbridge
(FDA, USA)



Aliza Thompson
(FDA, USA)




Ellis Unger
(FDA, USA)



George Van Hare
(FDA, USA)



Bernard Vasseur
(FDA, USA)



Changfu Wu
(FDA, USA)



Lisa Yanoff
(FDA, USA)



Emmanouil Zouridakis
(MHRA, GBR)



Bram Zuckerman
(FDA, USA)

Faculty members 2020

Patients



Jacqueline Alikhaani
(Los Angeles, USA)



Sadegh Alikhaani
(Los Angeles, USA)



Marc Bains
(Vancouver, CAN)



Cynthia Chauhan
(Wichita, USA)



Patrick Gee
(Chesterfield, USA)



Penilla Gunther
(Stockholm, SWE)



Nick Hartshorne-Evans
(Pumping Marvellous
Foundation, GBR)



Denis Janssen
(Zuid, NED)




Steve Macari
(Poitiers, FRA)



Robin Martinez
(Denver, USA)



Greg Merritt
(Ann Arbor, USA)



Wanda F Moore
(Arizona, USA)



Bray Patrick-Lake
(Durham, USA)



Juddson Rupp
(Charlotte, USA)




Lisa Salberg
(HCMA, USA)



Jeff Sloan
(Rochester, USA)

Faculty members 2020

Patients



Marjorie Smelstor
(Kansas City, USA)




Marietta Verbakel
(Nijmegen, NED)



Jayna Williams
(New Hampshire, USA)

Faculty members 2020

Payer/Economist



Andrew Briggs
(LSHTM, GBR)



Martin Cowie
(ex-NICE, GBR)



Adrian Jonas
(NICE, London, GBR)